1
|
Morris M, Cook A, Dodkins J, Price D, Waller S, Hassan S, Nathan A, Aggarwal A, Payne HA, Clarke N, van der Meulen J, Nossiter J. What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National Prostate Cancer Audit in England. BMJ Open 2024; 14:e078284. [PMID: 38418235 PMCID: PMC10910410 DOI: 10.1136/bmjopen-2023-078284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 01/30/2024] [Indexed: 03/01/2024] Open
Abstract
OBJECTIVES A national survey aimed to measure how men with prostate cancer perceived their involvement in and decisions around their care immediately after diagnosis. This study aimed to describe any differences found by socio-demographic groups. DESIGN Cross-sectional study of men who were diagnosed with and treated for prostate cancer. SETTING The National Prostate Cancer Audit patient-reported experience measures (PREMs) survey in England. PARTICIPANTS Men diagnosed in 2014-2016, with non-metastatic prostate cancer, were surveyed. Responses from 32 796 men were individually linked to records from a national clinical audit and to administrative hospital data. Age, ethnicity, deprivation and disease risk classification were used to explore variation in responses to selected questions. PRIMARY AND SECONDARY OUTCOME MEASURES Responses to five questions from the PREMs survey: the proportion responding to the highest positive category was compared across the socio-demographic characteristics above. RESULTS When adjusted for other factors, older men were less likely than men under the age of 60 to feel side effects had been explained in a way they could understand (men 80+: relative risk (RR)=0.92, 95% CI 0.84 to 1.00), that their views were considered (RR=0.79, 95% CI 0.73 to 0.87) or that they were involved in decisions (RR=0.92, 95% CI 0.85 to 1.00). The latter was also apparent for men who were not white (black men: RR=0.89, 95% CI 0.82 to 0.98; Asian men: RR=0.85, 95% CI 0.75 to 0.96) and, to a lesser extent, for more deprived men. CONCLUSIONS The observed discrepancies highlight the need for more focus on initiatives to improve the experience of ethnic minority patients and those older than 60 years. The findings also argue for further validation of discriminatory instruments to help cancer care providers fully understand the variation in the experience of their patients.
Collapse
Affiliation(s)
- Melanie Morris
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
- Health Services Research & Policy, London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy, London, UK
| | - Adrian Cook
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
| | - Joanna Dodkins
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
| | - Derek Price
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - Steve Waller
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
| | - Syreen Hassan
- Health Services Research & Policy, London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy, London, UK
| | - Arjun Nathan
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
| | - Ajay Aggarwal
- Health Services Research & Policy, London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy, London, UK
| | - Heather Ann Payne
- Consultant Clinical Oncologist, University College London Hospitals NHS Foundation Trust, London, London, UK
| | - Noel Clarke
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
- The Christie NHS Foundation Trust, Manchester, Manchester, UK
| | - Jan van der Meulen
- Health Services Research & Policy, London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy, London, UK
| | - Julie Nossiter
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
| |
Collapse
|
2
|
Dodkins J, Nossiter J, Cook A, Payne H, Clarke N, van der Meulen J, Aggarwal A. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review. Eur Urol Oncol 2024; 7:14-24. [PMID: 37380578 DOI: 10.1016/j.euo.2023.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 04/10/2023] [Accepted: 05/11/2023] [Indexed: 06/30/2023]
Abstract
CONTEXT Since 2015 there have been major advances in the management of primary metastatic hormone-sensitive prostate cancer (mHSPC) following the publication of key clinical trials that demonstrated significant clinical benefits with docetaxel chemotherapy or novel hormone therapy (NHT) in addition to androgen deprivation therapy (ADT). Despite these advances, there is evidence to show that these treatments are not being utilised for mHSPC in clinical practice. OBJECTIVE To determine the utilisation of docetaxel and NHT in mHSPC in routine practice and the determinants of variation in their use. EVIDENCE ACQUISITION MEDLINE and Embase were searched systematically for studies on utilisation of treatments for primary mHSPC that were based on regional or national data sets and published after January 2005. Study results were summarised using a narrative synthesis. EVIDENCE SYNTHESIS Thirteen papers were included in the analysis, six full-text articles and seven abstracts, on studies that included a total of 166 876 patients. The utilisation rate of treatment intensification with either docetaxel or NHT (enzalutamide, apalutamide, or abiraterone) in addition to ADT ranged from 9.3% to 38.1% across the studies. Younger, White patients with fewer comorbidities and living in more urban settings were more likely to be prescribed treatment intensification. Patients treated in private academic institutions by oncologists were more likely to receive docetaxel or NHT. Socioeconomic status did not impact receipt of systemic therapy. NHT utilisation rates appear to have increased over time. CONCLUSIONS These results highlight the need to change the approach to the treatment of primary mHSPC in the real world by harnessing the practice-changing results from recent trials in this setting to optimise upfront systemic therapy for this patient population. PATIENT SUMMARY We reviewed the use of treatments for primary metastatic hormone-sensitive prostate cancer that showed a benefit in key clinical trials. We found that these treatments are underused, particularly among certain patient groups.
Collapse
Affiliation(s)
- Joanna Dodkins
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK; London School of Hygiene and Tropical Medicine, London, UK.
| | - Julie Nossiter
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK; London School of Hygiene and Tropical Medicine, London, UK
| | - Adrian Cook
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
| | - Heather Payne
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Noel Clarke
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK; Department of Urology, The Christie and Salford Royal Hospitals, Manchester, UK
| | - Jan van der Meulen
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK; London School of Hygiene and Tropical Medicine, London, UK
| | - Ajay Aggarwal
- London School of Hygiene and Tropical Medicine, London, UK; Department of Oncology, Guy's and St. Thomas' NHS Foundation Trust, London, UK
| |
Collapse
|
3
|
Dodkins J, Cook A, Morris M, Nossiter J, Prust S, Waller S, van der Meulen J, Aggarwal A, Clarke N, Payne HA. Organisation and delivery of supportive services for patients with prostate cancer in the National Health Service in England and Wales: a national cross-sectional hospital survey and latent class analysis. BMJ Open 2023; 13:e071674. [PMID: 37989358 PMCID: PMC10668241 DOI: 10.1136/bmjopen-2023-071674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 09/29/2023] [Indexed: 11/23/2023] Open
Abstract
OBJECTIVES We assessed how often National Health Service (NHS) hospitals reported that they had specific supportive services for patients with prostate cancer available onsite, including nursing support, sexual function and urinary continence services, psychological and genetic counselling, and oncogeriatric services. We identified groups of hospitals with similar patterns of supportive services. DESIGN/SETTING We conducted an organisational survey in 2021 of all NHS hospitals providing prostate cancer services in England and Wales. Latent class analysis grouped hospitals with similar patterns of supportive services. RESULTS In 138 hospitals, an advanced prostate cancer nurse was available in 125 hospitals (90.6%), 107 (77.5%) had a clinical nurse specialist (CNS) attending all clinics, 103 (75.7%) had sexual function services, 111 (81.6%) had continence services and 93 (69.4%) psychological counselling. The availability of genetic counselling (41 hospitals, 30.6%) and oncogeriatric services (15 hospitals, 11.0%) was lower. The hospitals could be divided into three groups. The first and largest group of 85 hospitals provided the most comprehensive supportive services onsite: all hospitals had a CNS attending all clinics, 84 (98.8%) sexual function services and 73 (85.9%) continence services. A key characteristic of the second group of 31 hospitals was that none had a CNS attending all clinics. A key characteristic of the third group of 22 hospitals was that none had sexual function services available. The hospitals in the largest group were more likely to run joint clinics (p<0.001) and host the regional specialist multidisciplinary team (p=0.002). CONCLUSIONS There is considerable variation in supportive services for prostate cancer available onsite in NHS hospitals in England and Wales. Availability of genetic counselling and oncogeriatric services is low. The different patterns of supportive services among hospitals demonstrate that initiatives to improve the availability of the entire range of supportive services to all patients should be carefully targeted.
Collapse
Affiliation(s)
- Joanna Dodkins
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
- Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK
| | - Adrian Cook
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
| | - Melanie Morris
- Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
| | - Julie Nossiter
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
- Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK
| | - Steve Prust
- National Prostate Cancer Audit Patient and Public Involvement (PPI) Forum, Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
| | - Steve Waller
- National Prostate Cancer Audit Patient and Public Involvement (PPI) Forum, Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
| | - Jan van der Meulen
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
- Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK
| | - Ajay Aggarwal
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
- Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK
- Department of Oncology, Guy's & St Thomas' NHS Trust, London, UK
| | - Noel Clarke
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
- Department of Urology, The Christie and Salford Royal Hospitals, The Christie Hospital NHS Trust, Manchester, UK
| | - Heather Ann Payne
- Clinical Effectiveness Unit, Royal College of Surgeons, London, UK
- Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
| |
Collapse
|
4
|
Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. Eur J Cancer 2023; 191:112966. [PMID: 37542936 DOI: 10.1016/j.ejca.2023.112966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 06/16/2023] [Accepted: 06/28/2023] [Indexed: 08/07/2023]
Abstract
BACKGROUND In patients with advanced ovarian cancer, the modelled CA-125 ELIMination rate constant K (KELIM) is an early indicator of the tumour intrinsic chemosensitivity. We assessed the prognostic and surrogate values of KELIM with respect to those of surgery outcome (based on post-operative residual lesions) in the Gynaecologic Cancer Intergroup (GCIG) individual patient data meta-analysis MAOV (Meta-Analysis in OVarian cancer) built before the emergence of poly(ADP-ribose) polymerase (PARP) inhibitors. METHODS The dataset was split into learning and validation cohorts (ratio 1:2). The individual modelled KELIM values were estimated, standardised by the median value, then scored as unfavourable (<1.0) or favourable (≥1.0). Overall survival (OS) and progression-free survival (PFS) analyses were performed with a two-step meta-analytic approach and surrogacy through a two-level meta-analytic model. RESULTS KELIM was assessed in 5884 patients from eight first-line trials (learning, 1962; validation, 3922). A favourable KELIM score was significantly associated with longer OS (validation set, median, 78.8 versus 28.4 months, hazard-ratios [HR] 0.46, 95% confidence interval [CI], 0.41-0.50, C-index 0.68), and longer PFS (validation set, median 30.5 versus 9.8 months, HR 0.49, 95% CI, 0.45-0.54, C-index 0.68), as were International Federation of Gynaecology and Obstetrics (FIGO) stage and debulking surgery outcome. Three prognostic groups were identified based on the surgery outcome and KELIM score, with large differences in OS (105.1, ∼45.0, and 22.1 months) and PFS (58.1, ∼15.0, and 8.0 months). Surrogacy for OS and for PFS was not established. CONCLUSION KELIM is an independent prognostic biomarker for survival, complementary to surgery outcome, representing a new determinant of first-line treatment success.
Collapse
Affiliation(s)
- Pauline Corbaux
- EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France; Medical Oncology, Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne (ICHUSE), Centre Hospitalier Universitaire de Saint-Etienne, France
| | - Benoit You
- EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, GINECO, GINEGEPS, Lyon, France.
| | - Rosalind M Glasspool
- Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK
| | - Nozomu Yanaihara
- Department of Obstetrics and Gynecologye, The Jikei University School of Medicine, Tokyo, Japan
| | - Anna V Tinker
- Medical Oncology, BC Cancer - Vancouver, Vancouver, Canada
| | - Kristina Lindemann
- Department of Gynaecological Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | | | - Mansoor R Mirza
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Clinical Trial Unit, Nordic Society of Gynaecological Oncology, Copenhagen, Denmark
| | - Fabien Subtil
- Department of Biostatistics, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, CNRS UMR 5558, Claude Bernard University Lyon 1, Lyon, France
| | - Olivier Colomban
- EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France
| | - Julien Péron
- Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, GINECO, GINEGEPS, Lyon, France; Department of Biostatistics, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, CNRS UMR 5558, Claude Bernard University Lyon 1, Lyon, France
| | - Eleni Karamouza
- Institut Gustave Roussy, Office of Biostatistics and Epidemiology, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France
| | - Iain McNeish
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - Caroline Kelly
- Cancer Research UK Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Tatsuo Kagimura
- Foundation for Biomedical Research and Innovation at Kobe, Translational Research Center for Medical Innovation, Kobe, Japan
| | - Stephen Welch
- Department of Oncology, London Health Sciences Centre, London, Ontario, Canada
| | - Liz-Anne Lewsley
- Cancer Research UK Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | | | - Adrian Cook
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| |
Collapse
|
5
|
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol 2023; 24:443-456. [PMID: 37142371 DOI: 10.1016/s1470-2045(23)00148-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 03/17/2023] [Accepted: 03/23/2023] [Indexed: 05/06/2023]
Abstract
BACKGROUND Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival. METHODS We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland. Eligible patients (no age restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0-2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m2 intravenously for six cycles with prednisolone 10 mg orally once per day allowed from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 160 mg orally once a day (in the abiraterone and enzalutamide trial). Patients were stratified by centre, age, WHO performance status, type of androgen deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status, planned radiotherapy, and planned docetaxel use. The primary outcome was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who started treatment. A fixed-effects meta-analysis of individual patient data was used to compare differences in survival between the two trials. STAMPEDE is registered with ClinicalTrials.gov (NCT00268476) and ISRCTN (ISRCTN78818544). FINDINGS Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly assigned to standard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial. Median follow-up was 96 months (IQR 86-107) in the abiraterone trial and 72 months (61-74) in the abiraterone and enzalutamide trial. In the abiraterone trial, median overall survival was 76·6 months (95% CI 67·8-86·9) in the abiraterone group versus 45·7 months (41·6-52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53-0·73]; p<0·0001). In the abiraterone and enzalutamide trial, median overall survival was 73·1 months (61·9-81·3) in the abiraterone and enzalutamide group versus 51·8 months (45·3-59·0) in the standard of care group (HR 0·65 [0·55-0·77]; p<0·0001). We found no difference in the treatment effect between these two trials (interaction HR 1·05 [0·83-1·32]; pinteraction=0·71) or between-trial heterogeneity (I2 p=0·70). In the first 5 years of treatment, grade 3-5 toxic effects were higher when abiraterone was added to standard of care (271 [54%] of 498 vs 192 [38%] of 502 with standard of care) and the highest toxic effects were seen when abiraterone and enzalutamide were added to standard of care (302 [68%] of 445 vs 204 [45%] of 454 with standard of care). Cardiac causes were the most common cause of death due to adverse events (five [1%] with standard of care plus abiraterone and enzalutamide [two attributed to treatment] and one (<1%) with standard of care in the abiraterone trial). INTERPRETATION Enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. Clinically important improvements in survival from addition of abiraterone to androgen deprivation therapy are maintained for longer than 7 years. FUNDING Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.
Collapse
Affiliation(s)
- Gerhardt Attard
- Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK.
| | - Laura Murphy
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Noel W Clarke
- Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Ashwin Sachdeva
- Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Craig Jones
- Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Alex Hoyle
- Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | | | - Robert J Jones
- Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK
| | | | - Silke Gillessen
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; CH and Universita della Svizzera Italiana, Lugano, Switzerland
| | - Adrian Cook
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Chris Brawley
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Clare Gilson
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Hannah Rush
- Medical Research Council Clinical Trials Unit, University College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - Hoda Abdel-Aty
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - Claire L Amos
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Claire Murphy
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | | | - Zafar Malik
- Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
| | - J Martin Russell
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Nazia Parkar
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Cheryl Pugh
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Carlos Diaz-Montana
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | | | | | - Helen Saxby
- Torbay and South Devon NHS Foundation Trust, Torbay, UK
| | - Ian Pedley
- Northern Centre for Cancer Care, Newcastle upon Tyne, UK
| | | | - Alison Birtle
- Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK
| | | | | | | | | | | | | | - Emma Gray
- Yeovil District Hospital NHS Foundation Trust, Yeovil, UK
| | | | - Omi Parikh
- East Lancashire Hospitals NHS Trust, Preston, UK
| | | | | | - James Wylie
- Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Anjali Zarkar
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | - Richard Cathomas
- Division of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland
| | - Michael D Brown
- Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Yatin Jain
- Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - David P Dearnaley
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | | | - Duncan Gilbert
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Ruth E Langley
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Robin Millman
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - David Matheson
- Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK
| | - Matthew R Sydes
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Louise C Brown
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Mahesh K B Parmar
- Medical Research Council Clinical Trials Unit, University College London, London, UK
| | - Nicholas D James
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| |
Collapse
|
6
|
Colomban O, Clamp A, Cook A, McNeish IA, You B. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO Clin Cancer Inform 2023; 7:e2200188. [PMID: 37075255 PMCID: PMC10281428 DOI: 10.1200/cci.22.00188] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 02/02/2023] [Accepted: 02/17/2023] [Indexed: 04/21/2023] Open
Abstract
PURPOSE An international meta-analysis identified a group of patients with advanced epithelial ovarian cancer (EOC) with a very poor survival because of two unfavorable features: (1) a poor chemosensitivity defined by an unfavorable modeled CA-125 ELIMination rate constant K (KELIM) score <1.0 with the online calculator CA-125-Biomarker Kinetics, and (2) an incomplete debulking surgery. We assumed that patients belonging to this poor prognostic group would benefit from a fractionated densified chemotherapy regimen. METHODS The data set of ICON-8 phase III trial (ClinicalTrials.gov identifier: NCT01654146), where patients with EOC were treated with the standard three-weekly, or the weekly dose-dense, carboplatin-paclitaxel regimens and debulking primary surgery (immediate primary surgery [IPS] or delayed primary [or interval] surgery [DPS]), was investigated. The association between treatment arm efficacy, standardized KELIM (scored as favorable ≥1.0, or unfavorable <1.0), and surgery completeness was assessed by univariate/multivariate analyses in IPS and DPS cohorts. RESULTS Of 1,566 enrolled patients, KELIM was calculated with the online model in 1,334 with ≥3 CA-125 available values (85%). As previously reported, both KELIM and surgery completeness were complementary prognostic covariates, and could be combined into three prognostic groups with large OS differences: (1) good if favorable KELIM and complete surgery; (2) intermediate if either unfavorable KELIM or incomplete surgery; and (3) poor if unfavorable KELIM and incomplete surgery. Weekly dose-dense chemotherapy was associated with PFS/OS improvement in the poor prognostic group in both the IPS cohort (PFS: hazard ratio [HR], 0.50; 95% CI, 0.31 to 0.79; OS: HR, 0.58; 95% CI, 0.35 to 0.95) and the DPS cohort (PFS: HR, 0.53; 95% CI, 0.37 to 0.76; OS: HR, 0.57; 95% CI, 0.39 to 0.82). CONCLUSION Fractionated dose-dense chemotherapy might be beneficial for patients belonging to the poor prognostic group characterized by lower tumor chemosensitivity assessed with the online calculator CA-125-Biomarker Kinetics and incomplete debulking surgery. Further investigation in the future SALVOVAR trial is warranted.
Collapse
Affiliation(s)
- Olivier Colomban
- Faculté de Médecine Lyon-Sud, Université Lyon, Université Claude Bernard Lyon 1, EA3738 CICLY, Lyon, France
| | - Andrew Clamp
- The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
| | - Adrian Cook
- MRC Clinical Trials Unit at UCL, London, United Kingdom
| | - Iain A. McNeish
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Benoit You
- Faculté de Médecine Lyon-Sud, Université Lyon, Université Claude Bernard Lyon 1, EA3738 CICLY, Lyon, France
- Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Lyon, France
- Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens et du sein and GINEco Group on Early Phase Studies (GINECO-GINEGE PS), Paris, France
| |
Collapse
|
7
|
Foroutan F, Guyatt G, Stehlik J, Gustafsson F, Greig D, McDonald M, Bertolotti A, Kugathasan L, Rayner D, Cook A, Zlatanoski D, Ram S, Demas-Clarke P, Kozuszko S, Alba A. Use of Induction Therapy Post Heart Transplantation - Clinical Practice Recommendations Based on Systematic Review and Network Meta-Analysis of Evidence. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
8
|
Burdett S, Fisher D, Parker C, Sydes M, Pommier P, Sargos P, Spratt D, Kishan A, Brihoum M, Catton C, Chabaud S, Clarke N, Cook A, Latorzeff I, Tierney J, Vale C. LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Attard G, Murphy L, Clarke N, Cross W, Gillessen S, Amos C, Brawley C, Jones R, Pezaro C, Malik Z, Montazeri A, Millman R, Cook A, Gilbert D, Langley R, Parker C, Sydes M, Brown L, Parmar M, James N. LBA62 Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Haran Á, Jain Y, Hambrock T, Murphy L, Cook A, Brown L, Hoyle A, Sachdeva A, Ali S, Amos C, Sydes M, Attard G, Parmar M, James N, Clarke N. 1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
11
|
Parker C, Clarke N, Cook A, Catton C, Cross W, Kynaston H, Logue J, Petersen P, Neville P, Persad R, Payne H, Saad F, Stirling A, Parulekar W, Parmar M, Sydes M. LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
12
|
Parker CC, Clarke NW, Catton C, Kynaston H, Cook A, Cross W, Davidson C, Goldstein C, Logue J, Maniatis C, Petersen PM, Neville P, Payne H, Persad R, Pugh C, Stirling A, Saad F, Parulekar WR, Parmar MKB, Sydes MR. RADICALS-HD: Reflections before the Results are Known. Clin Oncol (R Coll Radiol) 2022; 34:593-597. [PMID: 35810050 DOI: 10.1016/j.clon.2022.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 06/01/2022] [Accepted: 06/15/2022] [Indexed: 11/16/2022]
Affiliation(s)
- C C Parker
- The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, UK.
| | - N W Clarke
- Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK; Department of Urology, Salford Royal Hospitals, Manchester, UK
| | - C Catton
- Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - H Kynaston
- Cardiff University School of Medicine, Cardiff University, Cardiff, UK
| | - A Cook
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - W Cross
- Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - C Davidson
- Canadian Cancer Trials Group, Queen's University, Kingston, Canada
| | - C Goldstein
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - J Logue
- Oncology, The Christie Hospital, Manchester, UK
| | - C Maniatis
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - P M Petersen
- Department of Oncology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
| | - P Neville
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - H Payne
- Oncology, University College London Hospitals, London, UK
| | - R Persad
- Bristol Urological Institute, North Bristol Hospitals, Bristol, UK
| | - C Pugh
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - A Stirling
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - F Saad
- University of Montreal Hospital Center (CHUM), Montréal, Canada
| | - W R Parulekar
- Canadian Cancer Trials Group, Queen's University, Kingston, Canada
| | - M K B Parmar
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - M R Sydes
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| |
Collapse
|
13
|
Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Aul R, Beirne P, Bolton CE, Brown JS, Choudhury G, Diar-Bakerly N, Easom N, Echevarria C, Fuld J, Hart N, Hurst J, Jones MG, Parekh D, Pfeffer P, Rahman NM, Rowland-Jones SL, Shah AM, Wootton DG, Chalder T, Davies MJ, De Soyza A, Geddes JR, Greenhalf W, Greening NJ, Heaney LG, Heller S, Howard LS, Jacob J, Jenkins RG, Lord JM, Man WDC, McCann GP, Neubauer S, Openshaw PJM, Porter JC, Rowland MJ, Scott JT, Semple MG, Singh SJ, Thomas DC, Toshner M, Lewis KE, Thwaites RS, Briggs A, Docherty AB, Kerr S, Lone NI, Quint J, Sheikh A, Thorpe M, Zheng B, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Harrison EM, Wain LV, Brightling CE, Abel K, Adamali H, Adeloye D, Adeyemi O, Adrego R, Aguilar Jimenez LA, Ahmad S, Ahmad Haider N, Ahmed R, Ahwireng N, Ainsworth M, Al-Sheklly B, Alamoudi A, Ali M, Aljaroof M, All AM, Allan L, Allen RJ, Allerton L, Allsop L, Almeida P, Altmann D, Alvarez Corral M, Amoils S, Anderson D, Antoniades C, Arbane G, Arias A, Armour C, Armstrong L, Armstrong N, Arnold D, Arnold H, Ashish A, Ashworth A, Ashworth M, Aslani S, Assefa-Kebede H, Atkin C, Atkin P, Aung H, Austin L, Avram C, Ayoub A, Babores M, Baggott R, Bagshaw J, Baguley D, Bailey L, Baillie JK, Bain S, Bakali M, Bakau M, Baldry E, Baldwin D, Ballard C, Banerjee A, Bang B, Barker RE, Barman L, Barratt S, Barrett F, Basire D, Basu N, Bates M, Bates A, Batterham R, Baxendale H, Bayes H, Beadsworth M, Beckett P, Beggs M, Begum M, Bell D, Bell R, Bennett K, Beranova E, Bermperi A, Berridge A, Berry C, Betts S, Bevan E, Bhui K, Bingham M, Birchall K, Bishop L, Bisnauthsing K, Blaikely J, Bloss A, Bolger A, Bonnington J, Botkai A, Bourne C, Bourne M, Bramham K, Brear L, Breen G, Breeze J, Bright E, Brill S, Brindle K, Broad L, Broadley A, Brookes C, Broome M, Brown A, Brown A, Brown J, Brown J, Brown M, Brown M, Brown V, Brugha T, Brunskill N, Buch M, Buckley P, Bularga A, Bullmore E, Burden L, Burdett T, Burn D, Burns G, Burns A, Busby J, Butcher R, Butt A, Byrne S, Cairns P, Calder PC, Calvelo E, Carborn H, Card B, Carr C, Carr L, Carson G, Carter P, Casey A, Cassar M, Cavanagh J, Chablani M, Chambers RC, Chan F, Channon KM, Chapman K, Charalambou A, Chaudhuri N, Checkley A, Chen J, Cheng Y, Chetham L, Childs C, Chilvers ER, Chinoy H, Chiribiri A, Chong-James K, Choudhury N, Chowienczyk P, Christie C, Chrystal M, Clark D, Clark C, Clarke J, Clohisey S, Coakley G, Coburn Z, Coetzee S, Cole J, Coleman C, Conneh F, Connell D, Connolly B, Connor L, Cook A, Cooper B, Cooper J, Cooper S, Copeland D, Cosier T, Coulding M, Coupland C, Cox E, Craig T, Crisp P, Cristiano D, Crooks MG, Cross A, Cruz I, Cullinan P, Cuthbertson D, Daines L, Dalton M, Daly P, Daniels A, Dark P, Dasgin J, David A, David C, Davies E, Davies F, Davies G, Davies GA, Davies K, Dawson J, Daynes E, Deakin B, Deans A, Deas C, Deery J, Defres S, Dell A, Dempsey K, Denneny E, Dennis J, Dewar A, Dharmagunawardena R, Dickens C, Dipper A, Diver S, Diwanji SN, Dixon M, Djukanovic R, Dobson H, Dobson SL, Donaldson A, Dong T, Dormand N, Dougherty A, Dowling R, Drain S, Draxlbauer K, Drury K, Dulawan P, Dunleavy A, Dunn S, Earley J, Edwards S, Edwardson C, El-Taweel H, Elliott A, Elliott K, Ellis Y, Elmer A, Evans D, Evans H, Evans J, Evans R, Evans RI, Evans T, Evenden C, Evison L, Fabbri L, Fairbairn S, Fairman A, Fallon K, Faluyi D, Favager C, Fayzan T, Featherstone J, Felton T, Finch J, Finney S, Finnigan J, Finnigan L, Fisher H, Fletcher S, Flockton R, Flynn M, Foot H, Foote D, Ford A, Forton D, Fraile E, Francis C, Francis R, Francis S, Frankel A, Fraser E, Free R, French N, Fu X, Furniss J, Garner L, Gautam N, George J, George P, Gibbons M, Gill M, Gilmour L, Gleeson F, Glossop J, Glover S, Goodman N, Goodwin C, Gooptu B, Gordon H, Gorsuch T, Greatorex M, Greenhaff PL, Greenhalgh A, Greenwood J, Gregory H, Gregory R, Grieve D, Griffin D, Griffiths L, Guerdette AM, Guillen Guio B, Gummadi M, Gupta A, Gurram S, Guthrie E, Guy Z, H Henson H, Hadley K, Haggar A, Hainey K, Hairsine B, Haldar P, Hall I, Hall L, Halling-Brown M, Hamil R, Hancock A, Hancock K, Hanley NA, Haq S, Hardwick HE, Hardy E, Hardy T, Hargadon B, Harrington K, Harris E, Harrison P, Harvey A, Harvey M, Harvie M, Haslam L, Havinden-Williams M, Hawkes J, Hawkings N, Haworth J, Hayday A, Haynes M, Hazeldine J, Hazelton T, Heeley C, Heeney JL, Heightman M, Henderson M, Hesselden L, Hewitt M, Highett V, Hillman T, Hiwot T, Hoare A, Hoare M, Hockridge J, Hogarth P, Holbourn A, Holden S, Holdsworth L, Holgate D, Holland M, Holloway L, Holmes K, Holmes M, Holroyd-Hind B, Holt L, Hormis A, Hosseini A, Hotopf M, Howard K, Howell A, Hufton E, Hughes AD, Hughes J, Hughes R, Humphries A, Huneke N, Hurditch E, Husain M, Hussell T, Hutchinson J, Ibrahim W, Ilyas F, Ingham J, Ingram L, Ionita D, Isaacs K, Ismail K, Jackson T, James WY, Jarman C, Jarrold I, Jarvis H, Jastrub R, Jayaraman B, Jezzard P, Jiwa K, Johnson C, Johnson S, Johnston D, Jolley CJ, Jones D, Jones G, Jones H, Jones H, Jones I, Jones L, Jones S, Jose S, Kabir T, Kaltsakas G, Kamwa V, Kanellakis N, Kaprowska S, Kausar Z, Keenan N, Kelly S, Kemp G, Kerslake H, Key AL, Khan F, Khunti K, Kilroy S, King B, King C, Kingham L, Kirk J, Kitterick P, Klenerman P, Knibbs L, Knight S, Knighton A, Kon O, Kon S, Kon SS, Koprowska S, Korszun A, Koychev I, Kurasz C, Kurupati P, Laing C, Lamlum H, Landers G, Langenberg C, Lasserson D, Lavelle-Langham L, Lawrie A, Lawson C, Lawson C, Layton A, Lea A, Lee D, Lee JH, Lee E, Leitch K, Lenagh R, Lewis D, Lewis J, Lewis V, Lewis-Burke N, Li X, Light T, Lightstone L, Lilaonitkul W, Lim L, Linford S, Lingford-Hughes A, Lipman M, Liyanage K, Lloyd A, Logan S, Lomas D, Loosley R, Lota H, Lovegrove W, Lucey A, Lukaschuk E, Lye A, Lynch C, MacDonald S, MacGowan G, Macharia I, Mackie J, Macliver L, Madathil S, Madzamba G, Magee N, Magtoto MM, Mairs N, Majeed N, Major E, Malein F, Malim M, Mallison G, Mandal S, Mangion K, Manisty C, Manley R, March K, Marciniak S, Marino P, Mariveles M, Marouzet E, Marsh S, Marshall B, Marshall M, Martin J, Martineau A, Martinez LM, Maskell N, Matila D, Matimba-Mupaya W, Matthews L, Mbuyisa A, McAdoo S, Weir McCall J, McAllister-Williams H, McArdle A, McArdle P, McAulay D, McCormick J, McCormick W, McCourt P, McGarvey L, McGee C, Mcgee K, McGinness J, McGlynn K, McGovern A, McGuinness H, McInnes IB, McIntosh J, McIvor E, McIvor K, McLeavey L, McMahon A, McMahon MJ, McMorrow L, Mcnally T, McNarry M, McNeill J, McQueen A, McShane H, Mears C, Megson C, Megson S, Mehta P, Meiring J, Melling L, Mencias M, Menzies D, Merida Morillas M, Michael A, Milligan L, Miller C, Mills C, Mills NL, Milner L, Misra S, Mitchell J, Mohamed A, Mohamed N, Mohammed S, Molyneaux PL, Monteiro W, Moriera S, Morley A, Morrison L, Morriss R, Morrow A, Moss AJ, Moss P, Motohashi K, Msimanga N, Mukaetova-Ladinska E, Munawar U, Murira J, Nanda U, Nassa H, Nasseri M, Neal A, Needham R, Neill P, Newell H, Newman T, Newton-Cox A, Nicholson T, Nicoll D, Nolan CM, Noonan MJ, Norman C, Novotny P, Nunag J, Nwafor L, Nwanguma U, Nyaboko J, O'Donnell K, O'Brien C, O'Brien L, O'Regan D, Odell N, Ogg G, Olaosebikan O, Oliver C, Omar Z, Orriss-Dib L, Osborne L, Osbourne R, Ostermann M, Overton C, Owen J, Oxton J, Pack J, Pacpaco E, Paddick S, Painter S, Pakzad A, Palmer S, Papineni P, Paques K, Paradowski K, Pareek M, Parfrey H, Pariante C, Parker S, Parkes M, Parmar J, Patale S, Patel B, Patel M, Patel S, Pattenadk D, Pavlides M, Payne S, Pearce L, Pearl JE, Peckham D, Pendlebury J, Peng Y, Pennington C, Peralta I, Perkins E, Peterkin Z, Peto T, Petousi N, Petrie J, Phipps J, Pimm J, Piper Hanley K, Pius R, Plant H, Plein S, Plekhanova T, Plowright M, Polgar O, Poll L, Porter J, Portukhay S, Powell N, Prabhu A, Pratt J, Price A, Price C, Price C, Price D, Price L, Price L, Prickett A, Propescu J, Pugmire S, Quaid S, Quigley J, Qureshi H, Qureshi IN, Radhakrishnan K, Ralser M, Ramos A, Ramos H, Rangeley J, Rangelov B, Ratcliffe L, Ravencroft P, Reddington A, Reddy R, Redfearn H, Redwood D, Reed A, Rees M, Rees T, Regan K, Reynolds W, Ribeiro C, Richards A, Richardson E, Rivera-Ortega P, Roberts K, Robertson E, Robinson E, Robinson L, Roche L, Roddis C, Rodger J, Ross A, Ross G, Rossdale J, Rostron A, Rowe A, Rowland A, Rowland J, Roy K, Roy M, Rudan I, Russell R, Russell E, Saalmink G, Sabit R, Sage EK, Samakomva T, Samani N, Sampson C, Samuel K, Samuel R, Sanderson A, Sapey E, Saralaya D, Sargant J, Sarginson C, Sass T, Sattar N, Saunders K, Saunders P, Saunders LC, Savill H, Saxon W, Sayer A, Schronce J, Schwaeble W, Scott K, Selby N, Sewell TA, Shah K, Shah P, Shankar-Hari M, Sharma M, Sharpe C, Sharpe M, Shashaa S, Shaw A, Shaw K, Shaw V, Shelton S, Shenton L, Shevket K, Short J, Siddique S, Siddiqui S, Sidebottom J, Sigfrid L, Simons G, Simpson J, Simpson N, Singh C, Singh S, Sissons D, Skeemer J, Slack K, Smith A, Smith D, Smith S, Smith J, Smith L, Soares M, Solano TS, Solly R, Solstice AR, Soulsby T, Southern D, Sowter D, Spears M, Spencer LG, Speranza F, Stadon L, Stanel S, Steele N, Steiner M, Stensel D, Stephens G, Stephenson L, Stern M, Stewart I, Stimpson R, Stockdale S, Stockley J, Stoker W, Stone R, Storrar W, Storrie A, Storton K, Stringer E, Strong-Sheldrake S, Stroud N, Subbe C, Sudlow CL, Suleiman Z, Summers C, Summersgill C, Sutherland D, Sykes DL, Sykes R, Talbot N, Tan AL, Tarusan L, Tavoukjian V, Taylor A, Taylor C, Taylor J, Te A, Tedd H, Tee CJ, Teixeira J, Tench H, Terry S, Thackray-Nocera S, Thaivalappil F, Thamu B, Thickett D, Thomas C, Thomas S, Thomas AK, Thomas-Woods T, Thompson T, Thompson AAR, Thornton T, Tilley J, Tinker N, Tiongson GF, Tobin M, Tomlinson J, Tong C, Touyz R, Tripp KA, Tunnicliffe E, Turnbull A, Turner E, Turner S, Turner V, Turner K, Turney S, Turtle L, Turton H, Ugoji J, Ugwuoke R, Upthegrove R, Valabhji J, Ventura M, Vere J, Vickers C, Vinson B, Wade E, Wade P, Wainwright T, Wajero LO, Walder S, Walker S, Walker S, Wall E, Wallis T, Walmsley S, Walsh JA, Walsh S, Warburton L, Ward TJC, Warwick K, Wassall H, Waterson S, Watson E, Watson L, Watson J, Welch C, Welch H, Welsh B, Wessely S, West S, Weston H, Wheeler H, White S, Whitehead V, Whitney J, Whittaker S, Whittam B, Whitworth V, Wight A, Wild J, Wilkins M, Wilkinson D, Williams N, Williams N, Williams J, Williams-Howard SA, Willicombe M, Willis G, Willoughby J, Wilson A, Wilson D, Wilson I, Window N, Witham M, Wolf-Roberts R, Wood C, Woodhead F, Woods J, Wormleighton J, Worsley J, Wraith D, Wrey Brown C, Wright C, Wright L, Wright S, Wyles J, Wynter I, Xu M, Yasmin N, Yasmin S, Yates T, Yip KP, Young B, Young S, Young A, Yousuf AJ, Zawia A, Zeidan L, Zhao B, Zongo O. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med 2022; 10:761-775. [PMID: 35472304 PMCID: PMC9034855 DOI: 10.1016/s2213-2600(22)00127-8] [Citation(s) in RCA: 144] [Impact Index Per Article: 72.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 03/23/2022] [Accepted: 03/31/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge. METHODS The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing. FINDINGS 2320 participants discharged from hospital between March 7, 2020, and April 18, 2021, were assessed at 5 months after discharge and 807 (32·7%) participants completed both the 5-month and 1-year visits. 279 (35·6%) of these 807 patients were women and 505 (64·4%) were men, with a mean age of 58·7 (SD 12·5) years, and 224 (27·8%) had received invasive mechanical ventilation (WHO class 7-9). The proportion of patients reporting full recovery was unchanged between 5 months (501 [25·5%] of 1965) and 1 year (232 [28·9%] of 804). Factors associated with being less likely to report full recovery at 1 year were female sex (odds ratio 0·68 [95% CI 0·46-0·99]), obesity (0·50 [0·34-0·74]) and invasive mechanical ventilation (0·42 [0·23-0·76]). Cluster analysis (n=1636) corroborated the previously reported four clusters: very severe, severe, moderate with cognitive impairment, and mild, relating to the severity of physical health, mental health, and cognitive impairment at 5 months. We found increased inflammatory mediators of tissue damage and repair in both the very severe and the moderate with cognitive impairment clusters compared with the mild cluster, including IL-6 concentration, which was increased in both comparisons (n=626 participants). We found a substantial deficit in median EQ-5D-5L utility index from before COVID-19 (retrospective assessment; 0·88 [IQR 0·74-1·00]), at 5 months (0·74 [0·64-0·88]) to 1 year (0·75 [0·62-0·88]), with minimal improvements across all outcome measures at 1 year after discharge in the whole cohort and within each of the four clusters. INTERPRETATION The sequelae of a hospital admission with COVID-19 were substantial 1 year after discharge across a range of health domains, with the minority in our cohort feeling fully recovered. Patient-perceived health-related quality of life was reduced at 1 year compared with before hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials. FUNDING UK Research and Innovation and National Institute for Health Research.
Collapse
|
14
|
James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz‐Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russell JM, Berthold DR, Buckner ML, Mason MD, Ritchie AWS, Birtle AJ, Brock SJ, Das P, Ford D, Gale J, Grant W, Gray EK, Hoskin P, Khan MM, Manetta C, McPhail NJ, O'Sullivan JM, Parikh O, Perna C, Pezaro CJ, Protheroe AS, Robinson AJ, Rudman SM, Sheehan DJ, Srihari NN, Syndikus I, Tanguay JS, Thomas CW, Vengalil S, Wagstaff J, Wylie JP, Parmar MKB, Sydes MR. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer 2022; 151:422-434. [PMID: 35411939 PMCID: PMC9321995 DOI: 10.1002/ijc.34018] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Revised: 02/15/2022] [Accepted: 02/22/2022] [Indexed: 11/17/2022]
Abstract
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC-alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly-diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow-up, 329 SOC-alone deaths (118 low-risk, 178 high-risk) and 244 SOC + AAP deaths (75 low-risk, 145 high-risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50-0.71; P = 0.31 × 10-9 ) favoured SOC + AAP, with 5-years survival improved from 41% SOC-alone to 60% SOC + AAP. This was similar in low-risk (HR = 0.55; 95% CI: 0.41-0.76) and high-risk (HR = 0.54; 95% CI: 0.43-0.69) patients. Median and current maximum time on SOC + AAP was 2.4 and 8.1 years. Toxicity at 4 years postrandomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group.
Collapse
Affiliation(s)
| | - Noel W. Clarke
- The Departments of Surgery & UrologyThe Christie & Salford Royal HospitalsManchesterUK
| | - Adrian Cook
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | - Adnan Ali
- The Christie NHS Foundation TrustManchesterUK
| | | | | | - Christopher D. Brawley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | - Simon Chowdhury
- Guy's, King's, & St. Thomas' Hospitals, and Sarah Cannon Research InstituteLondonUK
| | | | - David P. Dearnaley
- The Institute of Cancer Research and Royal Marsden NHS Foundation TrustLondonUK
| | | | - Carlos Diaz‐Montana
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | - Duncan Gilbert
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | - Silke Gillessen
- Istituto Oncologico della Svizzera ItalianaBellinzonaSwitzerland
| | - Clare Gilson
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
- Royal Marsden HospitalLondonUK
| | - Rob J. Jones
- Beatson West of Scotland Cancer Centre, University of GlasgowGlasgowUK
| | - Ruth E. Langley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | - Zafar I. Malik
- Radiotherapy UnitThe Clatterbridge Cancer Centre NHS Foundation TrustLiverpoolLiverpoolL7 8YAUK
| | - David J. Matheson
- School of Allied Health and Midwifery, Faculty of Education, Health and WellbeingUniversity of WolverhamptonWolverhamptonWS1 3BDUK
| | | | - Chris C. Parker
- Uro‐Oncology UnitRoyal Marsden Hospital and Institute of Cancer ResearchSuttonUK
| | - Cheryl Pugh
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | - Hannah Rush
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
- Guys and St Thomas' NHS Foundation TrustLondonUK
| | - J. Martin Russell
- Institute of Cancer Sciences, University of GlasgowGlasgowUK
- Beatson West of Scotland Cancer CentreGlasgowUK
| | | | - Michelle L. Buckner
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | | | | | - Alison J. Birtle
- Rosemere Cancer Centre, Lancashire Teaching Hospitals & University of Manchester, University of Central LancashireLancashireUK
| | | | - Prantik Das
- Department of OncologyUniversity Hospitals of Derby and Burton NHS Foundation TrustDerbyUK
| | - Dan Ford
- City Hospital, Cancer Centre at Queen Elizabeth HospitalBirminghamUK
| | - Joanna Gale
- Portsmouth Hospitals University TrustPortsmouthUK
| | - Warren Grant
- Gloucestershire Oncology Centre, Cheltenham General HospitalCheltenhamUK
| | | | | | - Mohammad M. Khan
- Department of Oncology Castle Hill HospitalHullUK
- Scarborough General HospitalScarboroughUK
| | | | | | - Joe M. O'Sullivan
- Patrick G Johnston Centre for Cancer Research, Queen's University BelfastBelfastUK
| | - Omi Parikh
- Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS TrustPrestonUK
| | - Carla Perna
- Royal Surrey NHS Foundation TrustGuildfordUK
| | | | | | | | | | | | | | - Isabel Syndikus
- Radiotherapy UnitThe Clatterbridge Cancer Centre NHS Foundation TrustLiverpoolLiverpoolL7 8YAUK
| | | | | | - Salil Vengalil
- University Hospital North Midlands NHS TrustStaffordshireUK
| | - John Wagstaff
- Swansea University and the South West UK Cancer CentreSwanseaUK
| | | | - Mahesh K. B. Parmar
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | - Matthew R. Sydes
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCLLondonUK
| | | |
Collapse
|
15
|
Kouli O, Murray V, Bhatia S, Cambridge WA, Kawka M, Shafi S, Knight SR, Kamarajah SK, McLean KA, Glasbey JC, Khaw RA, Ahmed W, Akhbari M, Baker D, Borakati A, Mills E, Thavayogan R, Yasin I, Raubenheimer K, Ridley W, Sarrami M, Zhang G, Egoroff N, Pockney P, Richards T, Bhangu A, Creagh-Brown B, Edwards M, Harrison EM, Lee M, Nepogodiev D, Pinkney T, Pearse R, Smart N, Vohra R, Sohrabi C, Jamieson A, Nguyen M, Rahman A, English C, Tincknell L, Kakodkar P, Kwek I, Punjabi N, Burns J, Varghese S, Erotocritou M, McGuckin S, Vayalapra S, Dominguez E, Moneim J, Salehi M, Tan HL, Yoong A, Zhu L, Seale B, Nowinka Z, Patel N, Chrisp B, Harris J, Maleyko I, Muneeb F, Gough M, James CE, Skan O, Chowdhury A, Rebuffa N, Khan H, Down B, Fatimah Hussain Q, Adams M, Bailey A, Cullen G, Fu YXJ, McClement B, Taylor A, Aitken S, Bachelet B, Brousse de Gersigny J, Chang C, Khehra B, Lahoud N, Lee Solano M, Louca M, Rozenbroek P, Rozitis E, Agbinya N, Anderson E, Arwi G, Barry I, Batchelor C, Chong T, Choo LY, Clark L, Daniels M, Goh J, Handa A, Hanna J, Huynh L, Jeon A, Kanbour A, Lee A, Lee J, Lee T, Leigh J, Ly D, McGregor F, Moss J, Nejatian M, O'Loughlin E, Ramos I, Sanchez B, Shrivathsa A, Sincari A, Sobhi S, Swart R, Trimboli J, Wignall P, Bourke E, Chong A, Clayton S, Dawson A, Hardy E, Iqbal R, Le L, Mao S, Marinelli I, Metcalfe H, Panicker D, R HH, Ridgway S, Tan HH, Thong S, Van M, Woon S, Woon-Shoo-Tong XS, Yu S, Ali K, Chee J, Chiu C, Chow YW, Duller A, Nagappan P, Ng S, Selvanathan M, Sheridan C, Temple M, Do JE, Dudi-Venkata NN, Humphries E, Li L, Mansour LT, Massy-Westropp C, Fang B, Farbood K, Hong H, Huang Y, Joan M, Koh C, Liu YHA, Mahajan T, Muller E, Park R, Tanudisastro M, Wu JJG, Chopra P, Giang S, Radcliffe S, Thach P, Wallace D, Wilkes A, Chinta SH, Li J, Phan J, Rahman F, Segaran A, Shannon J, Zhang M, Adams N, Bonte A, Choudhry A, Colterjohn N, Croyle JA, Donohue J, Feighery A, Keane A, McNamara D, Munir K, Roche D, Sabnani R, Seligman D, Sharma S, Stickney Z, Suchy H, Tan R, Yordi S, Ahmed I, Aranha M, El Sabawy D, Garwood P, Harnett M, Holohan R, Howard R, Kayyal Y, Krakoski N, Lupo M, McGilberry W, Nepon H, Scoleri Y, Urbina C, Ahmad Fuad MF, Ahmed O, Jaswantlal D, Kelly E, Khan MHT, Naidu D, Neo WX, O'Neill R, Sugrue M, Abbas JD, Abdul-Fattah S, Azlan A, Barry K, Idris NS, Kaka N, Mc Dermott D, Mohammad Nasir MN, Mozo M, Rehal A, Shaikh Yousef M, Wong RH, Curran E, Gardner M, Hogan A, Julka R, Lasser G, Ní Chorráin N, Ting J, Browne R, George S, Janjua Z, Leung Shing V, Megally M, Murphy S, Ravenscroft L, Vedadi A, Vyas V, Bryan A, Sheikh A, Ubhi J, Vannelli K, Vawda A, Adeusi L, Doherty C, Fitzgerald C, Gallagher H, Gill P, Hamza H, Hogan M, Kelly S, Larry J, Lynch P, Mazeni NA, O'Connell R, O'Loghlin R, Singh K, Abbas Syed R, Ali A, Alkandari B, Arnold A, Arora E, Azam R, Breathnach C, Cheema J, Compton M, Curran S, Elliott JA, Jayasamraj O, Mohammed N, Noone A, Pal A, Pandey S, Quinn P, Sheridan R, Siew L, Tan EP, Tio SW, Toh VTR, Walsh M, Yap C, Yassa J, Young T, Agarwal N, Almoosawy SA, Bowen K, Bruce D, Connachan R, Cook A, Daniell A, Elliott M, Fung HKF, Irving A, Laurie S, Lee YJ, Lim ZX, Maddineni S, McClenaghan RE, Muthuganesan V, Ravichandran P, Roberts N, Shaji S, Solt S, Toshney E, Arnold C, Baker O, Belais F, Bojanic C, Byrne M, Chau CYC, De Soysa S, Eldridge M, Fairey M, Fearnhead N, Guéroult A, Ho JSY, Joshi K, Kadiyala N, Khalid S, Khan F, Kumar K, Lewis E, Magee J, Manetta-Jones D, Mann S, McKeown L, Mitrofan C, Mohamed T, Monnickendam A, Ng AYKC, Ortu A, Patel M, Pope T, Pressling S, Purohit K, Saji S, Shah Foridi J, Shah R, Siddiqui SS, Surman K, Utukuri M, Varghese A, Williams CYK, Yang JJ, Billson E, Cheah E, Holmes P, Hussain S, Murdock D, Nicholls A, Patel P, Ramana G, Saleki M, Spence H, Thomas D, Yu C, Abousamra M, Brown C, Conti I, Donnelly A, Durand M, French N, Goan R, O'Kane E, Rubinchik P, Gardiner H, Kempf B, Lai YL, Matthews H, Minford E, Rafferty C, Reid C, Sheridan N, Al Bahri T, Bhoombla N, Rao BM, Titu L, Chatha S, Field C, Gandhi T, Gulati R, Jha R, Jones Sam MT, Karim S, Patel R, Saunders M, Sharma K, Abid S, Heath E, Kurup D, Patel A, Ali M, Cresswell B, Felstead D, Jennings K, Kaluarachchi T, Lazzereschi L, Mayson H, Miah JE, Reinders B, Rosser A, Thomas C, Williams H, Al-Hamid Z, Alsadoun L, Chlubek M, Fernando P, Gaunt E, Gercek Y, Maniar R, Ma R, Matson M, Moore S, Morris A, Nagappan PG, Ratnayake M, Rockall L, Shallcross O, Sinha A, Tan KE, Virdee S, Wenlock R, Donnelly HA, Ghazal R, Hughes I, Liu X, McFadden M, Misbert E, Mogey P, O'Hara A, Peace C, Rainey C, Raja P, Salem M, Salmon J, Tan CH, Alves D, Bahl S, Baker C, Coulthurst J, Koysombat K, Linn T, Rai P, Sharma A, Shergill A, Ahmed M, Ahmed S, Belk LH, Choudhry H, Cummings D, Dixon Y, Dobinson C, Edwards J, Flint J, Franco Da Silva C, Gallie R, Gardener M, Glover T, Greasley M, Hatab A, Howells R, Hussey T, Khan A, Mann A, Morrison H, Ng A, Osmond R, Padmakumar N, Pervaiz F, Prince R, Qureshi A, Sawhney R, Sigurdson B, Stephenson L, Vora K, Zacken A, Cope P, Di Traglia R, Ferarrio I, Hackett N, Healicon R, Horseman L, Lam LI, Meerdink M, Menham D, Murphy R, Nimmo I, Ramaesh A, Rees J, Soame R, Dilaver N, Adebambo D, Brown E, Burt J, Foster K, Kaliyappan L, Knight P, Politis A, Richardson E, Townsend J, Abdi M, Ball M, Easby S, Gill N, Ho E, Iqbal H, Matthews M, Nubi S, Nwokocha JO, Okafor I, Perry G, Sinartio B, Vanukuru N, Walkley D, Welch T, Yates J, Yeshitila N, Bryans K, Campbell B, Gray C, Keys R, Macartney M, Chamberlain G, Khatri A, Kucheria A, Lee STP, Reese G, Roy choudhury J, Tan WYR, Teh JJ, Ting A, Kazi S, Kontovounisios C, Vutipongsatorn K, Amarnath T, Balasubramanian N, Bassett E, Gurung P, Lim J, Panjikkaran A, Sanalla A, Alkoot M, Bacigalupo V, Eardley N, Horton M, Hurry A, Isti C, Maskell P, Nursiah K, Punn G, Salih H, Epanomeritakis E, Foulkes A, Henderson R, Johnston E, McCullough H, McLarnon M, Morrison E, Cheung A, Cho SH, Eriksson F, Hedges J, Low Z, May C, Musto L, Nagi S, Nur S, Salau E, Shabbir S, Thomas MC, Uthayanan L, Vig S, Zaheer M, Zeng G, Ashcroft-Quinn S, Brown R, Hayes J, McConville R, French R, Gilliam A, Sheetal S, Shehzad MU, Bani W, Christie I, Franklyn J, Khan M, Russell J, Smolarek S, Varadarassou R, Ahmed SK, Narayanaswamy S, Sealy J, Shah M, Dodhia V, Manukyan A, O'Hare R, Orbell J, Chung I, Forenc K, Gupta A, Agarwal A, Al Dabbagh A, Bennewith R, Bottomley J, Chu TSM, Chu YYA, Doherty W, Evans B, Hainsworth P, Hosfield T, Li CH, McCullagh I, Mehta A, Thaker A, Thompson B, Virdi A, Walker H, Wilkins E, Dixon C, Hassan MR, Lotca N, Tong KS, Batchelor-Parry H, Chaudhari S, Harris T, Hooper J, Johnson C, Mulvihill C, Nayler J, Olutobi O, Piramanayagam B, Stones K, Sussman M, Weaver C, Alam F, Al Rawi M, Andrew F, Arrayeh A, Azizan N, Hassan A, Iqbal Z, John I, Jones M, Kalake O, Keast M, Nicholas J, Patil A, Powell K, Roberts P, Sabri A, Segue AK, Shah A, Shaik Mohamed SA, Shehadeh A, Shenoy S, Tong A, Upcott M, Vijayasingam D, Anarfi S, Dauncey J, Devindaran A, Havalda P, Komninos G, Mwendwa E, Norman C, Richards J, Urquhart A, Allan J, Cahya E, Hunt H, McWhirter C, Norton R, Roxburgh C, Tan JY, Ali Butt S, Hansdot S, Haq I, Mootien A, Sanchez I, Vainas T, Deliyannis E, Tan M, Vipond M, Chittoor Satish NN, Dattani A, De Carvalho L, Gaston-Grubb M, Karunanithy L, Lowe B, Pace C, Raju K, Roope J, Taylor C, Youssef H, Munro T, Thorn C, Wong KHF, Yunus A, Chawla S, Datta A, Dinesh AA, Field D, Georgi T, Gwozdz A, Hamstead E, Howard N, Isleyen N, Jackson N, Kingdon J, Sagoo KS, Schizas A, Yin L, Aung E, Aung YY, Franklin S, Han SM, Kim WC, Martin Segura A, Rossi M, Ross T, Tirimanna R, Wang B, Zakieh O, Ben-Arzi H, Flach A, Jackson E, Magers S, Olu abara C, Rogers E, Sugden K, Tan H, Veliah S, Walton U, Asif A, Bharwada Y, Bowley D, Broekhuizen A, Cooper L, Evans N, Girdlestone H, Ling C, Mann H, Mehmood N, Mulvenna CL, Rainer N, Trout I, Gujjuri R, Jeyaraman D, Leong E, Singh D, Smith E, Anderton J, Barabas M, Goyal S, Howard D, Joshi A, Mitchell D, Weatherby T, Badminton R, Bird R, Burtle D, Choi NY, Devalia K, Farr E, Fischer F, Fish J, Gunn F, Jacobs D, Johnston P, Kalakoutas A, Lau E, Loo YNAF, Louden H, Makariou N, Mohammadi K, Nayab Y, Ruhomaun S, Ryliskyte R, Saeed M, Shinde P, Sudul M, Theodoropoulou K, Valadao-Spoorenberg J, Vlachou F, Arshad SR, Janmohamed AM, Noor M, Oyerinde O, Saha A, Syed Y, Watkinson W, Ahmadi H, Akintunde A, Alsaady A, Bradley J, Brothwood D, Burton M, Higgs M, Hoyle C, Katsura C, Lathan R, Louani A, Mandalia R, Prihartadi AS, Qaddoura B, Sandland-Taylor L, Thadani S, Thompson A, Walshaw J, Teo S, Ali S, Bawa JH, Fox S, Gargan K, Haider SA, Hanna N, Hatoum A, Khan Z, Krzak AM, Li T, Pitt J, Tan GJS, Ullah Z, Wilson E, Cleaver J, Colman J, Copeland L, Coulson A, Davis P, Faisal H, Hassan F, Hughes JT, Jabr Y, Mahmoud Ali F, Nahaboo Solim ZN, Sangheli A, Shaya S, Thompson R, Cornwall H, De Andres Crespo M, Fay E, Findlay J, Groves E, Jones O, Killen A, Millo J, Thomas S, Ward J, Wilkins M, Zaki F, Zilber E, Bhavra K, Bilolikar A, Charalambous M, Elawad A, Eleni A, Fawdon R, Gibbins A, Livingstone D, Mala D, Oke SE, Padmakumar D, Patsalides MA, Payne D, Ralphs C, Roney A, Sardar N, Stefanova K, Surti F, Timms R, Tosney G, Bannister J, Clement NS, Cullimore V, Kamal F, Lendor J, McKay J, Mcswiggan J, Minhas N, Seneviratne K, Simeen S, Valverde J, Watson N, Bloom I, Dinh TH, Hirniak J, Joseph R, Kansagra M, Lai CKN, Melamed N, Patel J, Randev J, Sedighi T, Shurovi B, Sodhi J, Vadgama N, Abdulla S, Adabavazeh B, Champion A, Chennupati R, Chu K, Devi S, Haji A, Schulz J, Testa F, Davies P, Gurung B, Howell S, Modi P, Pervaiz A, Zahid M, Abdolrazaghi S, Abi Aoun R, Anjum Z, Bawa G, Bhardwaj R, Brown S, Enver M, Gill D, Gopikrishna D, Gurung D, Kanwal A, Kaushal P, Khanna A, Lovell E, McEvoy C, Mirza M, Nabeel S, Naseem S, Pandya K, Perkins R, Pulakal R, Ray M, Reay C, Reilly S, Round A, Seehra J, Shakeel NM, Singh B, Vijay Sukhnani M, Brown L, Desai B, Elzanati H, Godhaniya J, Kavanagh E, Kent J, Kishor A, Liu A, Norwood M, Shaari N, Wood C, Wood M, Brown A, Chellapuri A, Ferriman A, Ghosh I, Kulkarni N, Noton T, Pinto A, Rajesh S, Varghese B, Wenban C, Aly R, Barciela C, Brookes T, Corrin E, Goldsworthy M, Mohamed Azhar MS, Moore J, Nakhuda S, Ng D, Pillay S, Port S, Abdullah M, Akinyemi J, Islam S, Kale A, Lewis A, Manjunath T, McCabe H, Misra S, Stubley T, Tam JP, Waraich N, Chaora T, Ford C, Osinkolu I, Pong G, Rai J, Risquet R, Ainsworth J, Ayandokun P, Barham E, Barrett G, Barry J, Bisson E, Bridges I, Burke D, Cann J, Cloney M, Coates S, Cripps P, Davies C, Francis N, Green S, Handley G, Hathaway D, Hurt L, Jenkins S, Johnston C, Khadka A, McGee U, Morris D, Murray R, Norbury C, Pierrepont Z, Richards C, Ross O, Ruddy A, Salmon C, Shield M, Soanes K, Spencer N, Taverner S, Williams C, Wills-Wood W, Woodward S, Chow J, Fan J, Guest O, Hunter I, Moon WY, Arthur-Quarm S, Edwards P, Hamlyn V, McEneaney L, N D G, Pranoy S, Ting M, Abada S, Alawattegama LH, Ashok A, Carey C, Gogna A, Haglund C, Hurley P, Leelo N, Liu B, Mannan F, Paramjothy K, Ramlogan K, Raymond-Hayling O, Shanmugarajah A, Solichan D, Wilkinson B, Ahmad NA, Allan D, Amin A, Bakina C, Burns F, Cameron F, Campbell A, Cavanagh S, Chan SMZ, Chapman S, Chong V, Edelsten E, Ekpete O, El Sheikh M, Ghose R, Hassane A, Henderson C, Hilton-Christie S, Husain M, Hussain H, Javid Z, Johnson-Ogbuneke J, Johnston A, Khalil M, Leung TCC, Makin I, Muralidharan V, Naeem M, Patil P, Ravichandran S, Saraeva D, Shankey-Smith W, Sharma N, Swan R, Waudby-West R, Wilkinson A, Wright K, Balasubramanian A, Bhatti S, Chalkley M, Chou WK, Dixon M, Evans L, Fisher K, Gandhi P, Ho S, Lau YB, Lowe S, Meechan C, Murali N, Musonda C, Njoku P, Ochieng L, Pervez MU, Seebah K, Shaikh I, Sikder MA, Vanker R, Alom J, Bajaj V, Coleman O, Finch G, Goss J, Jenkins C, Kontothanassis A, Liew MS, Ng K, Outram M, Shakeel MM, Tawn J, Zuhairy S, Chapple K, Cinnamond A, Coleman S, George HA, Goulder L, Hare N, Hawksley J, Kret A, Luesley A, Mecia L, Porter H, Puddy E, Richardson G, Sohail B, Srikaran V, Tadross D, Tobin J, Tokidis E, Young L, Ashdown T, Bratsos S, Koomson A, Kufuor A, Lim MQ, Shah S, Thorne EPC, Warusavitarne J, Xu S, Abigail S, Ahmed A, Ahmed J, Akmal A, Al-Khafaji M, Amini B, Arshad M, Bogie E, Brazkiewicz M, Carroll M, Chandegra A, Cirelli C, Deng A, Fairclough S, Fung YJ, Gornell C, Green RL, Green SV, Gulamhussein AHM, Isaac AG, Jan R, Jegatheeswaran L, Knee M, Kotecha J, Kotecha S, Maxwell-Armstrong C, McIntyre C, Mendis N, Naing TKP, Oberman J, Ong ZX, Ramalingam A, Saeed Adam A, Tan LL, Towell S, Yadav J, Anandampillai R, Chung S, Hounat A, Ibrahim B, Jeyakumar G, Khalil A, Khan UA, Nair G, Owusu-Ayim M, Wilson M, Kanani A, Kilkelly B, Ogunmwonyi I, Ong L, Samra B, Schomerus L, Shea J, Turner O, Yang Y, Amin M, Blott N, Clark A, Feather A, Forrest M, Hague S, Hamilton K, Higginbotham G, Hope E, Karimian S, Loveday K, Malik H, McKenna O, Noor A, Onsiong C, Patel B, Radcliffe N, Shah P, Tye L, Verma K, Walford R, Yusufi U, Zachariah M, Casey A, Doré C, Fludder V, Fortescue L, Kalapu SS, Karel E, Khera G, Smith C, Appleton B, Ashaye A, Boggon E, Evans A, Faris Mahmood H, Hinchcliffe Z, Marei O, Silva I, Spooner C, Thomas G, Timlin M, Wellington J, Yao SL, Abdelrazek M, Abdelrazik Y, Bee F, Joseph A, Mounce A, Parry G, Vignarajah N, Biddles D, Creissen A, Kolhe S, K T, Lea A, Ledda V, O'Loughlin P, Scanlon J, Shetty N, Weller C, Abdalla M, Adeoye A, Bhatti M, Chadda KR, Chu J, Elhakim H, Foster-Davies H, Rabie M, Tailor B, Webb S, Abdelrahim ASA, Choo SY, Jiwa A, Mangam S, Murray S, Shandramohan A, Aghanenu O, Budd W, Hayre J, Khanom S, Liew ZY, McKinney R, Moody N, Muhammad-Kamal H, Odogwu J, Patel D, Roy C, Sattar Z, Shahrokhi N, Sinha I, Thomson E, Wonga L, Bain J, Khan J, Ricardo D, Bevis R, Cherry C, Darkwa S, Drew W, Griffiths E, Konda N, Madani D, Mak JKC, Meda B, Odunukwe U, Preest G, Raheel F, Rajaseharan A, Ramgopal A, Risbrooke C, Selvaratnam K, Sethunath G, Tabassum R, Taylor J, Thakker A, Wijesingha N, Wybrew R, Yasin T, Ahmed Osman A, Alfadhel S, Carberry E, Chen JY, Drake I, Glen P, Jayasuriya N, Kawar L, Myatt R, Sinan LOH, Siu SSY, Tjen V, Adeboyejo O, Bacon H, Barnes R, Birnie C, D'Cunha Kamath A, Hughes E, Middleton S, Owen R, Schofield E, Short C, Smith R, Wang H, Willett M, Zimmerman M, Balfour J, Chadwick T, Coombe-Jones M, Do Le HP, Faulkner G, Hobson K, Shehata Z, Beattie M, Chmielewski G, Chong C, Donnelly B, Drusch B, Ellis J, Farrelly C, Feyi-Waboso J, Hibell I, Hoade L, Ho C, Jones H, Kodiatt B, Lidder P, Ni Cheallaigh L, Norman R, Patabendi I, Penfold H, Playfair M, Pomeroy S, Ralph C, Rottenburg H, Sebastian J, Sheehan M, Stanley V, Welchman J, Ajdarpasic D, Antypas A, Azouaghe O, Basi S, Bettoli G, Bhattarai S, Bommireddy L, Bourne K, Budding J, Cookey-Bresi R, Cummins T, Davies G, Fabelurin C, Gwilliam R, Hanley J, Hird A, Kruczynska A, Langhorne B, Lund J, Lutchman I, McGuinness R, Neary M, Pampapathi S, Pang E, Podbicanin S, Rai N, Redhouse White G, Sujith J, Thomas P, Walker I, Winterton R, Anderson P, Barrington M, Bhadra K, Clark G, Fowler G, Gibson C, Hudson S, Kaminskaite V, Lawday S, Longshaw A, MacKrill E, McLachlan F, Murdeshwar A, Nieuwoudt R, Parker P, Randall R, Rawlins E, Reeves SA, Rye D, Sirkis T, Sykes B, Ventress N, Wosinska N, Akram B, Burton L, Coombs A, Long R, Magowan D, Ong C, Sethi M, Williams G, Chan C, Chan LH, Fernando D, Gaba F, Khor Z, Les JW, Mak R, Moin S, Ng Kee Kwong KC, Paterson-Brown S, Tew YY, Bardon A, Burrell K, Coldwell C, Costa I, Dexter E, Hardy A, Khojani M, Mazurek J, Raymond T, Reddy V, Reynolds J, Soma A, Agiotakis S, Alsusa H, Desai N, Peristerakis I, Adcock A, Ayub H, Bennett T, Bibi F, Brenac S, Chapman T, Clarke G, Clark F, Galvin C, Gwyn-Jones A, Henry-Blake C, Kerner S, Kiandee M, Lovett A, Pilecka A, Ravindran R, Siddique H, Sikand T, Treadwell K, Akmal K, Apata A, Barton O, Broad G, Darling H, Dhuga Y, Emms L, Habib S, Jain R, Jeater J, Kan CYP, Kathiravelupillai A, Khatkar H, Kirmani S, Kulasabanathan K, Lacey H, Lal K, Manafa C, Mansoor M, McDonald S, Mittal A, Mustoe S, Nottrodt L, Oliver P, Papapetrou I, Pattinson F, Raja M, Reyhani H, Shahmiri A, Small O, Soni U, Aguirrezabala Armbruster B, Bunni J, Hakim MA, Hawkins-Hooker L, Howell KA, Hullait R, Jaskowska A, Ottewell L, Thomas-Jones I, Vasudev A, Clements B, Fenton J, Gill M, Haider S, Lim AJM, Maguire H, McMullan J, Nicoletti J, Samuel S, Unais MA, White N, Yao PC, Yow L, Boyle C, Brady R, Cheekoty P, Cheong J, Chew SJHL, Chow R, Ganewatta Kankanamge D, Mamer L, Mohammed B, Ng Chieng Hin J, Renji Chungath R, Royston A, Sharrad E, Sinclair R, Tingle S, Treherne K, Wyatt F, Maniarasu VS, Moug S, Appanna T, Bucknall T, Hussain F, Owen A, Parry M, Parry R, Sagua N, Spofforth K, Yuen ECT, Bosley N, Hardie W, Moore T, Regas C, Abdel-Khaleq S, Ali N, Bashiti H, Buxton-Hopley R, Constantinides M, D'Afflitto M, Deshpande A, Duque Golding J, Frisira E, Germani Batacchi M, Gomaa A, Hay D, Hutchison R, Iakovou A, Iakovou D, Ismail E, Jefferson S, Jones L, Khouli Y, Knowles C, Mason J, McCaughan R, Moffatt J, Morawala A, Nadir H, Neyroud F, Nikookam Y, Parmar A, Pinto L, Ramamoorthy R, Richards E, Thomson S, Trainer C, Valetopoulou A, Vassiliou A, Wantman A, Wilde S, Dickinson M, Rockall T, Senn D, Wcislo K, Zalmay P, Adelekan K, Allen K, Bajaj M, Gatumbu P, Hang S, Hashmi Y, Kaur T, Kawesha A, Kisiel A, Woodmass M, Adelowo T, Ahari D, Alhwaishel K, Atherton R, Clayton B, Cockroft A, Curtis Lopez C, Hilton M, Ismail N, Kouadria M, Lee L, MacConnachie A, Monks F, Mungroo S, Nikoletopoulou C, Pearce L, Sara X, Shahid A, Suresh G, Wilcha R, Atiyah A, Davies E, Dermanis A, Gibbons H, Hyde A, Lawson A, Lee C, Leung-Tack M, Li Saw Hee J, Mostafa O, Nair D, Pattani N, Plumbley-Jones J, Pufal K, Ramesh P, Sanghera J, Saram S, Scadding S, See S, Stringer H, Torrance A, Vardon H, Wyn-Griffiths F, Brew A, Kaur G, Soni D, Tickle A, Akbar Z, Appleyard T, Figg K, Jayawardena P, Johnson A, Kamran Siddiqui Z, Lacy-Colson J, Oatham R, Rowlands B, Sludden E, Turnbull C, Allin D, Ansar Z, Azeez Z, Dale VH, Garg J, Horner A, Jones S, Knight S, McGregor C, McKenna J, McLelland T, Packham-Smith A, Rowsell K, Spector-Hill I, Adeniken E, Baker J, Bartlett M, Chikomba L, Connell B, Deekonda P, Dhar M, Elmansouri A, Gamage K, Goodhew R, Hanna P, Knight J, Luca A, Maasoumi N, Mahamoud F, Manji S, Marwaha PK, Mason F, Oluboyede A, Pigott L, Razaq AM, Richardson M, Saddaoui I, Wijeyendram P, Yau S, Atkins W, Liang K, Miles N, Praveen B, Ashai S, Braganza J, Common J, Cundy A, Davies R, Guthrie J, Handa I, Iqbal M, Ismail R, Jones C, Jones I, Lee KS, Levene A, Okocha M, Olivier J, Smith A, Subramaniam E, Tandle S, Wang A, Watson A, Wilson C, Chan XHF, Khoo E, Montgomery C, Norris M, Pugalenthi PP, Common T, Cook E, Mistry H, Shinmar HS, Agarwal G, Bandyopadhyay S, Brazier B, Carroll L, Goede A, Harbourne A, Lakhani A, Lami M, Larwood J, Martin J, Merchant J, Pattenden S, Pradhan A, Raafat N, Rothwell E, Shammoon Y, Sudarshan R, Vickers E, Wingfield L, Ashworth I, Azizi S, Bhate R, Chowdhury T, Christou A, Davies L, Dwaraknath M, Farah Y, Garner J, Gureviciute E, Hart E, Jain A, Javid S, Kankam HK, Kaur Toor P, Kaz R, Kermali M, Khan I, Mattson A, McManus A, Murphy M, Nair K, Ngemoh D, Norton E, Olabiran A, Parry L, Payne T, Pillai K, Price S, Punjabi K, Raghunathan A, Ramwell A, Raza M, Ritehnia J, Simpson G, Smith W, Sodeinde S, Studd L, Subramaniam M, Thomas J, Towey S, Tsang E, Tuteja D, Vasani J, Vio M, Badran A, Adams J, Anthony Wilkinson J, Asvandi S, Austin T, Bald A, Bix E, Carrick M, Chander B, Chowdhury S, Cooper Drake B, Crosbie S, D Portela S, Francis D, Gallagher C, Gillespie R, Gravett H, Gupta P, Ilyas C, James G, Johny J, Jones A, Kinder F, MacLeod C, Macrow C, Maqsood-Shah A, Mather J, McCann L, McMahon R, Mitham E, Mohamed M, Munton E, Nightingale K, O'Neill K, Onyemuchara I, Senior R, Shanahan A, Sherlock J, Spyridoulias A, Stavrou C, Stokes D, Tamang R, Taylor E, Trafford C, Uden C, Waddington C, Yassin D, Zaman M, Bangi S, Cheng T, Chew D, Hussain N, Imani-Masouleh S, Mahasivam G, McKnight G, Ng HL, Ota HC, Pasha T, Ravindran W, Shah K, Vishnu K S, Zaman S, Carr W, Cope S, Eagles EJ, Howarth-Maddison M, Li CY, Reed J, Ridge A, Stubbs T, Teasdaled D, Umar R, Worthington J, Dhebri A, Kalenderov R, Alattas A, Arain Z, Bhudia R, Chia D, Daniel S, Dar T, Garland H, Girish M, Hampson A, Kyriacou H, Lehovsky K, Mullins W, Omorphos N, Vasdev N, Venkatesh A, Waldock W, Bhandari A, Brown G, Choa G, Eichenauer CE, Ezennia K, Kidwai Z, Lloyd-Thomas A, Macaskill Stewart A, Massardi C, Sinclair E, Skajaa N, Smith M, Tan I, Afsheen N, Anuar A, Azam Z, Bhatia P, Davies-kelly N, Dickinson S, Elkawafi M, Ganapathy M, Gupta S, Khoury EG, Licudi D, Mehta V, Neequaye S, Nita G, Tay VL, Zhao S, Botsa E, Cuthbert H, Elliott J, Furlepa M, Lehmann J, Mangtani A, Narayan A, Nazarian S, Parmar C, Shah D, Shaw C, Zhao Z, Beck C, Caldwell S, Clements JM, French B, Kenny R, Kirk S, Lindsay J, McClung A, McLaughlin N, Watson S, Whiteside E, Alyacoubi S, Arumugam V, Beg R, Dawas K, Garg S, Lloyd ER, Mahfouz Y, Manobharath N, Moonesinghe R, Morka N, Patel K, Prashar J, Yip S, Adeeko ES, Ajekigbe F, Bhat A, Evans C, Farrugia A, Gurung C, Long T, Malik B, Manirajan S, Newport D, Rayer J, Ridha A, Ross E, Saran T, Sinker A, Waruingi D, Allen R, Al Sadek Y, Alves do Canto Brum H, Asharaf H, Ashman M, Balakumar V, Barrington J, Baskaran R, Berry A, Bhachoo H, Bilal A, Boaden L, Chia WL, Covell G, Crook D, Dadnam F, Davis L, De Berker H, Doyle C, Fox C, Gruffydd-Davies M, Hafouda Y, Hill A, Hubbard E, Hunter A, Inpadhas V, Jamshaid M, Jandu G, Jeyanthi M, Jones T, Kantor C, Kwak SY, Malik N, Matt R, McNulty P, Miles C, Mohomed A, Myat P, Niharika J, Nixon A, O'Reilly D, Parmar K, Pengelly S, Price L, Ramsden M, Turnor R, Wales E, Waring H, Wu M, Yang T, Ye TTS, Zander A, Zeicu C, Bellam S, Francombe J, Kawamoto N, Rahman MR, Sathyanarayana A, Tang HT, Cheung J, Hollingshead J, Page V, Sugarman J, Wong E, Chiong J, Fung E, Kan SY, Kiang J, Kok J, Krahelski O, Liew MY, Lyell B, Sharif Z, Speake D, Alim L, Amakye NY, Chandrasekaran J, Chandratreya N, Drake J, Owoso T, Thu YM, Abou El Ela Bourquin B, Alberts J, Chapman D, Rehnnuma N, Ainsworth K, Carpenter H, Emmanuel T, Fisher T, Gabrel M, Guan Z, Hollows S, Hotouras A, Ip Fung Chun N, Jaffer S, Kallikas G, Kennedy N, Lewinsohn B, Liu FY, Mohammed S, Rutherfurd A, Situ T, Stammer A, Taylor F, Thin N, Urgesi E, Zhang N, Ahmad MA, Bishop A, Bowes A, Dixit A, Glasson R, Hatta S, Hatt K, Larcombe S, Preece J, Riordan E, Fegredo D, Haq MZ, Li C, McCann G, Stewart D, Baraza W, Bhullar D, Burt G, Coyle J, Deans J, Devine A, Hird R, Ikotun O, Manchip G, Ross C, Storey L, Tan WWL, Tse C, Warner C, Whitehead M, Wu F, Court EL, Crisp E, Huttman M, Mayes F, Robertson H, Rosen H, Sandberg C, Smith H, Al Bakry M, Ashwell W, Bajaj S, Bandyopadhyay D, Browlee O, Burway S, Chand CP, Elsayeh K, Elsharkawi A, Evans E, Ferrin S, Fort-Schaale A, Iacob M, I K, Impelliziere Licastro G, Mankoo AS, Olaniyan T, Otun J, Pereira R, Reddy R, Saeed D, Simmonds O, Singhal G, Tron K, Wickstone C, Williams R, Bradshaw E, De Kock Jewell V, Houlden C, Knight C, Metezai H, Mirza-Davies A, Seymour Z, Spink D, Wischhusen S. Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study. Lancet Digit Health 2022; 4:e520-e531. [PMID: 35750401 DOI: 10.1016/s2589-7500(22)00069-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2021] [Revised: 01/07/2022] [Accepted: 04/06/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Stratifying risk of postoperative pulmonary complications after major abdominal surgery allows clinicians to modify risk through targeted interventions and enhanced monitoring. In this study, we aimed to identify and validate prognostic models against a new consensus definition of postoperative pulmonary complications. METHODS We did a systematic review and international external validation cohort study. The systematic review was done in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched MEDLINE and Embase on March 1, 2020, for articles published in English that reported on risk prediction models for postoperative pulmonary complications following abdominal surgery. External validation of existing models was done within a prospective international cohort study of adult patients (≥18 years) undergoing major abdominal surgery. Data were collected between Jan 1, 2019, and April 30, 2019, in the UK, Ireland, and Australia. Discriminative ability and prognostic accuracy summary statistics were compared between models for the 30-day postoperative pulmonary complication rate as defined by the Standardised Endpoints in Perioperative Medicine Core Outcome Measures in Perioperative and Anaesthetic Care (StEP-COMPAC). Model performance was compared using the area under the receiver operating characteristic curve (AUROCC). FINDINGS In total, we identified 2903 records from our literature search; of which, 2514 (86·6%) unique records were screened, 121 (4·8%) of 2514 full texts were assessed for eligibility, and 29 unique prognostic models were identified. Nine (31·0%) of 29 models had score development reported only, 19 (65·5%) had undergone internal validation, and only four (13·8%) had been externally validated. Data to validate six eligible models were collected in the international external validation cohort study. Data from 11 591 patients were available, with an overall postoperative pulmonary complication rate of 7·8% (n=903). None of the six models showed good discrimination (defined as AUROCC ≥0·70) for identifying postoperative pulmonary complications, with the Assess Respiratory Risk in Surgical Patients in Catalonia score showing the best discrimination (AUROCC 0·700 [95% CI 0·683-0·717]). INTERPRETATION In the pre-COVID-19 pandemic data, variability in the risk of pulmonary complications (StEP-COMPAC definition) following major abdominal surgery was poorly described by existing prognostication tools. To improve surgical safety during the COVID-19 pandemic recovery and beyond, novel risk stratification tools are required. FUNDING British Journal of Surgery Society.
Collapse
|
16
|
Jalavu T, Cook A, Zemlin A. M076 Cost implications of dual and duplicate amylase and lipase requesting in the work up of acute pancreatitis at Tygerberg Tertiary Hospital, Cape Town, South Africa. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
17
|
Foroutan F, Guyatt G, Stehlik J, Gustafsson F, Greig D, McDonald M, Badiwala M, Bertolotti A, Kugathasan L, Cook A, Zlatanoski D, Ram S, Demas-Clarke P, Kozuszko S, Alba A. Use of Induction Therapy Post Heart Transplantation: A Heart Transplant Rapid Recommendations. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
18
|
Ngoi NY, Syn NL, Goh RM, Goh BC, Huang RYJ, Soon YY, James E, Cook A, Clamp A, Tan DS. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. Cochrane Database Syst Rev 2022; 2:CD012007. [PMID: 35188221 PMCID: PMC8859866 DOI: 10.1002/14651858.cd012007.pub2] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases were diagnosed in 2018, with 184,799 deaths. The lack of an effective screening strategy has led to the majority of women being diagnosed at an advanced stage. For these women, intravenous carboplatin combined with paclitaxel for six cycles is widely accepted as the standard first-line treatment for epithelial ovarian cancer, in combination with debulking surgery. However, there is conflicting evidence regarding the optimal dosing schedule of paclitaxel when combined with carboplatin in this setting. OBJECTIVES To compare the efficacy and tolerability of intravenous weekly paclitaxel with that of tri-weekly paclitaxel, in combination with intravenous carboplatin, as first-line treatment for epithelial ovarian cancer (defined as epithelial ovarian, primary peritoneal and fallopian tube cancer). SEARCH METHODS We searched CENTRAL, MEDLINE, and Embase databases for relevant studies up to 15 November 2021, using keywords and MeSH terms. We additionally handsearched conference libraries, online clinical trial databases and screened through lists of retrieved references. SELECTION CRITERIA We Included randomised controlled trials (RCTs) comparing weekly paclitaxel in combination with carboplatin versus tri-weekly paclitaxel in combination with carboplatin, for treatment of newly-diagnosed epithelial ovarian cancer. DATA COLLECTION AND ANALYSIS We used the hazard ratio (HR) to estimate the primary efficacy outcomes progression-free (PFS) and overall survival (OS). We used the risk ratio (RR) to estimate the primary toxicity outcome of severe neutropenia and secondary outcomes of quality of life (QoL) and treatment-related adverse events. Two review authors independently selected studies, extracted data, and assessed risk of bias, using standard Cochrane methodological procedures. We included individual participant data (IPD) from one of the included studies, ICON-8, provided by the study team. We analysed data using a random-effects model in Review Manager 5.4 software. Additionally, we reconstructed IPD for PFS and OS data from published Kaplan-Meier curves from all studies and subsequently pooled these to analyse the two primary efficacy outcomes. MAIN RESULTS From 2469 records, we identified four eligible RCTs with data for 3699 participants. All eligible studies were included in the main meta-analysis and reported on PFS and OS. There was likely a slight improvement in PFS when paclitaxel was dosed weekly compared to tri-weekly (HR 0.89, 95% confidence interval (CI) 0.81 to 0.98; 4 studies, 3699 participants; moderate-certainty evidence). We found little to no improvement in OS when paclitaxel was dosed weekly compared to tri-weekly (HR 0.92, 95% CI 0.79 to 1.06; 4 studies, 3699 participants; high-certainty evidence). There was likely little to no difference in high-grade (grade 3 or 4) neutropenia when paclitaxel was dosed weekly compared to tri-weekly (RR 1.11, 95% CI 0.86 to 1.43; 4 studies, 3639 participants; moderate-certainty evidence). However, weekly paclitaxel increased high-grade (grade 3 or 4) anaemia when compared to tri-weekly dosing (RR 1.57, 95% CI 1.12 to 2.20; 4 studies, 3639 participants; high-certainty evidence). There may be little to no difference in high-grade neuropathy when paclitaxel was dosed weekly compared to tri-weekly (RR 1.12, 95% CI 0.64 to 1.94; 4 studies, 3639 participants; low-certainty evidence). The overall risk of detection bias and performance bias was low for OS, but was unclear for other outcomes, as treatments were not blinded. The risk of bias in other domains was low or unclear. We note that OS data were immature for three of the included studies (GOG-0262, ICON-8 and MITO-7). AUTHORS' CONCLUSIONS Weekly paclitaxel combined with carboplatin for first-line treatment of epithelial ovarian cancer likely improves PFS slightly (moderate-certainty evidence) but not OS (high-certainty evidence), compared to tri-weekly paclitaxel combined with carboplatin. However, this was associated with increased risk for high-grade anaemia, treatment discontinuation, dose delays and dose omissions (high- to low-certainty evidence). Our findings may not apply to women receiving bevacizumab in first-line therapy, those receiving treatment in the neo-adjuvant setting, or those with rare subtypes of clear cell or mucinous ovarian cancer.
Collapse
Affiliation(s)
- Natalie Yl Ngoi
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
| | - Nicholas Lx Syn
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
- Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Robby M Goh
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
| | - Boon Cher Goh
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
| | - Ruby Yun-Ju Huang
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| | - Yu Yang Soon
- Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore
| | - Elizabeth James
- Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK
| | - Adrian Cook
- Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK
| | - Andrew Clamp
- Department of Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK
| | - David Sp Tan
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| |
Collapse
|
19
|
Forde P, Kindler H, Zauderer M, Sun Z, Ramalingam S, Anagnostou V, Brahmer J, Nowak A, Kok P, Brown C, Yip S, Cook A, Lesterhuis W, Hughes B, Pavlakis N, Stockler M, O'Byrne K. DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.10.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399:447-460. [PMID: 34953525 PMCID: PMC8811484 DOI: 10.1016/s0140-6736(21)02437-5] [Citation(s) in RCA: 157] [Impact Index Per Article: 78.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 11/02/2021] [Accepted: 11/03/2021] [Indexed: 01/05/2023]
Abstract
BACKGROUND Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population. METHODS These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8-10, and prostate-specific antigen [PSA] concentration ≥40 ng/mL) or relapsing with high-risk features (≤12 months of total ADT with an interval of ≥12 months without treatment and PSA concentration ≥4 ng/mL with a doubling time of <6 months, or a PSA concentration ≥20 ng/mL, or nodal relapse) non-metastatic prostate cancer, and a WHO performance status of 0-2. Local radiotherapy (as per local guidelines, 74 Gy in 37 fractions to the prostate and seminal vesicles or the equivalent using hypofractionated schedules) was mandated for node negative and encouraged for node positive disease. In both trials, patients were randomly assigned (1:1), by use of a computerised algorithm, to ADT alone (control group), which could include surgery and luteinising-hormone-releasing hormone agonists and antagonists, or with oral abiraterone acetate (1000 mg daily) and oral prednisolone (5 mg daily; combination-therapy group). In the second trial with no overlapping controls, the combination-therapy group also received enzalutamide (160 mg daily orally). ADT was given for 3 years and combination therapy for 2 years, except if local radiotherapy was omitted when treatment could be delivered until progression. In this primary analysis, we used meta-analysis methods to pool events from both trials. The primary endpoint of this meta-analysis was metastasis-free survival. Secondary endpoints were overall survival, prostate cancer-specific survival, biochemical failure-free survival, progression-free survival, and toxicity and adverse events. For 90% power and a one-sided type 1 error rate set to 1·25% to detect a target hazard ratio for improvement in metastasis-free survival of 0·75, approximately 315 metastasis-free survival events in the control groups was required. Efficacy was assessed in the intention-to-treat population and safety according to the treatment started within randomised allocation. STAMPEDE is registered with ClinicalTrials.gov, NCT00268476, and with the ISRCTN registry, ISRCTN78818544. FINDINGS Between Nov 15, 2011, and March 31, 2016, 1974 patients were randomly assigned to treatment. The first trial allocated 455 to the control group and 459 to combination therapy, and the second trial, which included enzalutamide, allocated 533 to the control group and 527 to combination therapy. Median age across all groups was 68 years (IQR 63-73) and median PSA 34 ng/ml (14·7-47); 774 (39%) of 1974 patients were node positive, and 1684 (85%) were planned to receive radiotherapy. With median follow-up of 72 months (60-84), there were 180 metastasis-free survival events in the combination-therapy groups and 306 in the control groups. Metastasis-free survival was significantly longer in the combination-therapy groups (median not reached, IQR not evaluable [NE]-NE) than in the control groups (not reached, 97-NE; hazard ratio [HR] 0·53, 95% CI 0·44-0·64, p<0·0001). 6-year metastasis-free survival was 82% (95% CI 79-85) in the combination-therapy group and 69% (66-72) in the control group. There was no evidence of a difference in metatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently compared with abiraterone acetate alone (interaction HR 1·02, 0·70-1·50, p=0·91) and no evidence of between-trial heterogeneity (I2 p=0·90). Overall survival (median not reached [IQR NE-NE] in the combination-therapy groups vs not reached [103-NE] in the control groups; HR 0·60, 95% CI 0·48-0·73, p<0·0001), prostate cancer-specific survival (not reached [NE-NE] vs not reached [NE-NE]; 0·49, 0·37-0·65, p<0·0001), biochemical failure-free-survival (not reached [NE-NE] vs 86 months [83-NE]; 0·39, 0·33-0·47, p<0·0001), and progression-free-survival (not reached [NE-NE] vs not reached [103-NE]; 0·44, 0·36-0·54, p<0·0001) were also significantly longer in the combination-therapy groups than in the control groups. Adverse events grade 3 or higher during the first 24 months were, respectively, reported in 169 (37%) of 451 patients and 130 (29%) of 455 patients in the combination-therapy and control groups of the abiraterone trial, respectively, and 298 (58%) of 513 patients and 172 (32%) of 533 patients of the combination-therapy and control groups of the abiraterone and enzalutamide trial, respectively. The two most common events more frequent in the combination-therapy groups were hypertension (abiraterone trial: 23 (5%) in the combination-therapy group and six (1%) in control group; abiraterone and enzalutamide trial: 73 (14%) and eight (2%), respectively) and alanine transaminitis (abiraterone trial: 25 (6%) in the combination-therapy group and one (<1%) in control group; abiraterone and enzalutamide trial: 69 (13%) and four (1%), respectively). Seven grade 5 adverse events were reported: none in the control groups, three in the abiraterone acetate and prednisolone group (one event each of rectal adenocarcinoma, pulmonary haemorrhage, and a respiratory disorder), and four in the abiraterone acetate and prednisolone with enzalutamide group (two events each of septic shock and sudden death). INTERPRETATION Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population. FUNDING Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.
Collapse
Affiliation(s)
- Gerhardt Attard
- Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK.
| | - Laura Murphy
- MRC Clinical Trials Unit at University College London, London, UK
| | - Noel W Clarke
- The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | | | | | | | - Silke Gillessen
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Universita della Svizzera Italiana, Lugano, Switzerland
| | - Adrian Cook
- MRC Clinical Trials Unit at University College London, London, UK
| | - Chris Brawley
- MRC Clinical Trials Unit at University College London, London, UK
| | - Claire L Amos
- MRC Clinical Trials Unit at University College London, London, UK
| | - Nafisah Atako
- MRC Clinical Trials Unit at University College London, London, UK
| | - Cheryl Pugh
- MRC Clinical Trials Unit at University College London, London, UK
| | - Michelle Buckner
- MRC Clinical Trials Unit at University College London, London, UK
| | | | - Zafar Malik
- Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
| | | | - Clare Gilson
- MRC Clinical Trials Unit at University College London, London, UK
| | - Hannah Rush
- MRC Clinical Trials Unit at University College London, London, UK
| | - Jo Bowen
- Cheltenham General Hospital, Cheltenham, UK
| | - Anna Lydon
- Torbay and South Devon NHS Foundation Trust, Torbay, UK
| | - Ian Pedley
- Northern Centre for Cancer Care, Newcastle upon Tyne, UK
| | | | | | | | | | | | | | | | | | - Emma Gray
- Yeovil District Hospital NHS Foundation Trust, Yeovil, UK; Musgrove Park Hospital, Taunton, UK
| | | | - Omi Parikh
- Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
| | | | - Isabel Syndikus
- Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
| | - James Wylie
- The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Anjali Zarkar
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | | | - Johann S de Bono
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - David P Dearnaley
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | | | - Duncan Gilbert
- MRC Clinical Trials Unit at University College London, London, UK
| | - Ruth E Langley
- MRC Clinical Trials Unit at University College London, London, UK
| | - Robin Millman
- MRC Clinical Trials Unit at University College London, London, UK
| | - David Matheson
- Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK
| | - Matthew R Sydes
- MRC Clinical Trials Unit at University College London, London, UK
| | - Louise C Brown
- MRC Clinical Trials Unit at University College London, London, UK
| | | | - Nicholas D James
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| |
Collapse
|
21
|
Barker TP, Steele N, Swamy G, Cook A, Rai A, Crawford R, Lutchman L. Infographic: Long-term core outcomes in cauda equina syndrome. Bone Joint J 2021; 103-B:1462-1463. [PMID: 34465157 DOI: 10.1302/0301-620x.103b9.bjj-2021-1152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- T P Barker
- Norfolk and Norwich University Hospital, Norwich, UK.,Colchester General Hospital, Colchester, UK
| | - N Steele
- Norfolk and Norwich University Hospital, Norwich, UK
| | - G Swamy
- Norfolk and Norwich University Hospital, Norwich, UK
| | - A Cook
- Norfolk and Norwich University Hospital, Norwich, UK
| | - A Rai
- Norfolk and Norwich University Hospital, Norwich, UK
| | - R Crawford
- Norfolk and Norwich University Hospital, Norwich, UK
| | - L Lutchman
- Norfolk and Norwich University Hospital, Norwich, UK
| |
Collapse
|
22
|
Corbaux P, You B, Glasspool R, Yanaihara N, Tinker A, Lindemann K, Ray-Coquard I, Mirza M, Subtil F, Colomban O, Peron J, Karamouza E, McNeish I, Hinsley S, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A. 751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1193] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
23
|
Attard G, Brown L, Clarke N, Murphy L, Cross W, Jones R, Gillessen S, Russell J, Cook A, Bowen J, Lydon A, Pedley I, Parikh O, Chowdhury S, Malik Z, Matheson D, Parker C, Sydes M, Parmar M, James N. LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2098] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
24
|
Frangou E, Bertelli G, Love S, Mackean MJ, Glasspool RM, Fotopoulou C, Cook A, Nicum S, Lord R, Ferguson M, Roux RL, Martinez M, Butcher C, Hulbert-Williams N, Howells L, Blagden SP. OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer. Gynecol Oncol 2021; 162:431-439. [PMID: 34059348 DOI: 10.1016/j.ygyno.2021.05.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 05/22/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (OC) and depression is also common. To date there have been no randomized trials assessing the impact of psychological intervention on depression and FOP in this patient group. PATIENTS AND METHODS Patients with primary or recurrent OC who had recently completed chemotherapy were eligible if they scored between 5 and 19 on the PHQ-9 depression and were randomized 1:1 to Intervention (3 standardized CBT-based sessions in the 6-12 weeks post-chemotherapy) or Control (standard of care). PHQ-9, FOP-Q-SF, EORTC QLQ C30 and OV28 questionnaires were then completed every 3 months for up to 2 years. The primary endpoint was change in PHQ-9 at 3 months. Secondary endpoints were change in other scores at 3 months and all scores at later timepoints. RESULTS 182 patients registered; 107 were randomized; 54 to Intervention and 53 to Control; mean age 59 years; 75 (70%) had completed chemotherapy for primary and 32 (30%) for relapsed OC and 67 patients completed both baseline and 3-month questionnaires. Improvement in PHQ-9 was observed for patients in both study arms at three months compared to baseline but there was no significant difference in change between Intervention and Control. A significant improvement on FOP-Q-SF scores was seen in the Intervention arm, whereas for those in the Control arm FOP-Q-SF scores deteriorated at 3 months (intervention effect = -4.4 (-7.57, -1.22), p-value = 0.008). CONCLUSIONS CBT-based psychological support provided after chemotherapy did not significantly alter the spontaneously improving trajectory of depression scores at three months but caused a significant improvement in FOP. Our findings call for the routine implementation of FOP support for ovarian cancer patients.
Collapse
Affiliation(s)
- E Frangou
- Centre for Statistics and Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; MRC Clinical Trials Unit at UCL, London, UK
| | | | - S Love
- Centre for Statistics and Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; MRC Clinical Trials Unit at UCL, London, UK
| | - M J Mackean
- Edinburgh Cancer Centre Western General Hospital, Edinburgh, UK
| | | | - C Fotopoulou
- Ovarian Cancer Action Research Centre, Hammersmith Hospital, Imperial College London, London, UK
| | - A Cook
- Gloucester Oncology Centre, Cheltenham, UK
| | - S Nicum
- Churchill Hospital, University of Oxford, Oxford, UK
| | - R Lord
- Clatterbridge Cancer Centre, Wirral, UK
| | | | - R L Roux
- Churchill Hospital, University of Oxford, Oxford, UK
| | - M Martinez
- Ovarian Cancer Action Research Centre, Hammersmith Hospital, Imperial College London, London, UK
| | - C Butcher
- Oncology Clinical Trials Office (OCTO), University of Oxford, Oxford, UK
| | | | - L Howells
- Research Team, Maggie's Centres, London, UK
| | - S P Blagden
- Churchill Hospital, University of Oxford, Oxford, UK.
| |
Collapse
|
25
|
Ali A, Hoyle A, Haran ÁM, Brawley CD, Cook A, Amos C, Calvert J, Douis H, Mason MD, Dearnaley D, Attard G, Gillessen S, Parmar MKB, Parker CC, Sydes MR, James ND, Clarke NW. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2021; 7:555-563. [PMID: 33599706 PMCID: PMC7893550 DOI: 10.1001/jamaoncol.2020.7857] [Citation(s) in RCA: 58] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Accepted: 11/06/2020] [Indexed: 02/02/2023]
Abstract
IMPORTANCE Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies with bone metastasis counts and metastatic site. OBJECTIVE To evaluate the association of bone metastasis count and location with survival benefit from prostate RT. DESIGN, SETTING, AND PARTICIPANTS This exploratory analysis of treatment outcomes based on metastatic site and extent as determined by conventional imaging (computed tomography/magnetic resonance imaging and bone scan) evaluated patients with newly diagnosed metastatic prostate cancer randomized within the STAMPEDE trial's metastasis M1 RT comparison. The association of baseline bone metastasis counts with overall survival (OS) and failure-free survival (FFS) was assessed using a multivariable fractional polynomial interaction procedure. Further analysis was conducted in subgroups. INTERVENTIONS Patients were randomized to receive either standard of care (androgen deprivation therapy with or without docetaxel) or standard of care and prostate RT. MAIN OUTCOMES AND MEASURES The primary outcomes were OS and FFS. RESULTS A total of 1939 of 2061 men were included (median [interquartile range] age, 68 [63-73] years); 1732 (89%) had bone metastases. Bone metastasis counts were associated with OS and FFS benefit from prostate RT. Survival benefit decreased continuously as the number of bone metastases increased, with benefit most pronounced up to 3 bone metastases. A plot of estimated treatment effect indicated that the upper 95% CI crossed the line of equivalence (hazard ratio [HR], 1) above 3 bone metastases without a detectable change point. Further analysis based on subgroups showed that the magnitude of benefit from the addition of prostate RT was greater in patients with low metastatic burden with only nonregional lymph nodes (M1a) or 3 or fewer bone metastases without visceral metastasis (HR for OS, 0.62; 95% CI, 0.46-0.83; HR for FFS, 0.57; 95% CI, 0.47-0.70) than among patients with 4 or more bone metastases or any visceral/other metastasis (HR for OS, 1.08; 95% CI, 0.91-1.28; interaction P = .003; HR for FFS, 0.87; 95% CI, 0.76-0.99; interaction P = .002). CONCLUSIONS AND RELEVANCE In this exploratory analysis of a randomized clinical trial, bone metastasis count and metastasis location based on conventional imaging were associated with OS and FFS benefit from prostate RT in M1 disease. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00268476; ISRCTN.com Identifier: ISRCTN78818544.
Collapse
Affiliation(s)
- Adnan Ali
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
- FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom
- Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - Alex Hoyle
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
- FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom
- Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom
- Department of Urology, The Salford NHS Foundation Trust, Manchester, United Kingdom
| | - Áine M. Haran
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
- FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom
- Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom
- Department of Urology, The Salford NHS Foundation Trust, Manchester, United Kingdom
| | - Christopher D. Brawley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom
| | - Adrian Cook
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom
| | - Claire Amos
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom
| | - Joanna Calvert
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom
| | - Hassan Douis
- Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | | | - David Dearnaley
- Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
| | | | - Silke Gillessen
- Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Università della Svizzera Italiana, Lugano, Switzerland
| | - Mahesh K. B. Parmar
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom
| | | | - Matthew R. Sydes
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom
| | - Nicholas D. James
- Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
| | - Noel W. Clarke
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
- FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom
- Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom
- Department of Urology, The Salford NHS Foundation Trust, Manchester, United Kingdom
| |
Collapse
|
26
|
Soveral I, Crispi F, Walter C, Guirado L, García-Cañadilla P, Cook A, Bonnin A, Dejea H, Rovira-Zurriaga C, Sánchez de Toledo J, Gratacós E, Martínez JM, Bijnens B, Gómez O. Early cardiac remodeling in aortic coarctation: insights from fetal and neonatal functional and structural assessment. Ultrasound Obstet Gynecol 2020; 56:837-849. [PMID: 31909552 DOI: 10.1002/uog.21970] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Revised: 12/12/2019] [Accepted: 12/23/2019] [Indexed: 06/10/2023]
Abstract
OBJECTIVES Coarctation of the aorta (CoA) is associated with left ventricular (LV) dysfunction in neonates and adults. Cardiac structure and function in fetal CoA and cardiac adaptation to early neonatal life have not been described. We aimed to investigate the presence of cardiovascular structural remodeling and dysfunction in fetuses with CoA and their early postnatal cardiac adaptation. METHODS This was a prospective observational case-control study, conducted between 2011 and 2018 in a single tertiary referral center, of fetuses with CoA and gestational age-matched normal controls. All fetuses/neonates underwent comprehensive echocardiographic evaluation in the third trimester of pregnancy and after birth. Additionally, myocardial microstructure was assessed in one fetal and one neonatal CoA-affected heart specimen, using synchrotron radiation-based X-ray phase-contrast microcomputed tomography and histology, respectively. RESULTS We included 30 fetuses with CoA and 60 gestational age-matched controls. Of these, 20 CoA neonates and 44 controls were also evaluated postnatally. Fetuses with CoA showed significant left-to-right volume redistribution, with right ventricular (RV) size and output dominance and significant geometry alterations with an abnormally elongated LV, compared with controls (LV midventricular sphericity index (median (interquartile range; IQR), 2.4 (2.0-2.7) vs 1.8 (1.7-2.0); P < 0.001). Biventricular function was preserved and no ventricular hypertrophy was observed. Synchrotron tomography and histological assessment revealed normal myocyte organization in the fetal and neonatal specimens, respectively. Postnatally, the LV in CoA cases showed prompt remodeling, becoming more globular (LV midventricular sphericity index (mean ± SD), 1.5 ± 0.3 in CoA vs 1.8 ± 0.2 in controls; P < 0.001) with preserved systolic and normalized output, but altered diastolic, parameters compared with controls (LV inflow peak velocity in early diastole (mean ± SD), 97.8 ± 14.5 vs 56.5 ± 12.9 cm/s; LV inflow peak velocity in atrial contraction (median (IQR), 70.5 (60.1-84.9) vs 47.0 (43.0-55.0) cm/s; LV peak myocardial velocity in atrial contraction (mean ± SD), 5.1 ± 2.6 vs 6.3 ± 2.2 cm/s; P < 0.05). The neonatal RV showed increased longitudinal function in the presence of a patent arterial duct. CONCLUSIONS Our results suggest unique fetal cardiac remodeling in CoA, in which the LV stays smaller from the decreased growth stimulus of reduced volume load. Postnatally, the LV is acutely volume-loaded, resulting in an overall geometry change with higher filling velocities and preserved systolic function. These findings improve our understanding of the evolution of CoA from fetal to neonatal life. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- I Soveral
- BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Barcelona, Spain
| | - F Crispi
- BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - C Walter
- Pediatric Cardiology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - L Guirado
- BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Barcelona, Spain
| | - P García-Cañadilla
- PhySense, DTIC, Universitat Pompeu Fabra, Barcelona, Spain
- Institute of Cardiovascular Science, University College London, London, UK
| | - A Cook
- Institute of Cardiovascular Science, University College London, London, UK
| | - A Bonnin
- Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland
| | - H Dejea
- Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland
- Institute for Biomedical Engineering, ETH Zürich, Zürich, Switzerland
| | - C Rovira-Zurriaga
- Department of Pathology, Hospital Sant Joan de Déu, Barcelona, Spain
| | | | - E Gratacós
- BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - J M Martínez
- BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| | - B Bijnens
- PhySense, DTIC, Universitat Pompeu Fabra, Barcelona, Spain
- ICREA, Barcelona, Spain
| | - O Gómez
- BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain
| |
Collapse
|
27
|
Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar MKB, Tierney JF. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 2020; 396:1422-1431. [PMID: 33002431 PMCID: PMC7611137 DOI: 10.1016/s0140-6736(20)31952-8] [Citation(s) in RCA: 193] [Impact Index Per Article: 48.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 07/13/2020] [Accepted: 07/27/2020] [Indexed: 12/28/2022]
Abstract
BACKGROUND It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic review of randomised controlled trials (RCTs) comparing these radiotherapy approaches. METHODS We used a prospective framework for adaptive meta-analysis (FAME), starting the review process while eligible trials were ongoing. RCTs were eligible if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy, following radical prostatectomy in men (age ≥18 years) with intermediate-risk or high-risk, localised or locally advanced prostate cancer. We searched trial registers and conference proceedings until July 8, 2020, to identify eligible RCTs. By establishing the ARTISTIC collaboration with relevant trialists, we were able to anticipate when eligible trial results would emerge, and we developed and registered a protocol with PROSPERO before knowledge of the trial results (CRD42019132669). We used a harmonised definition of event-free survival, as the time from randomisation until the first evidence of either biochemical progression (prostate-specific antigen [PSA] ≥0·4 ng/mL and rising after completion of any postoperative radiotherapy), clinical or radiological progression, initiation of a non-trial treatment, death from prostate cancer, or a PSA level of at least 2·0 ng/mL at any time after randomisation. We predicted when we would have sufficient power to assess whether adjuvant radiotherapy was superior to early salvage radiotherapy. Investigators supplied results for event-free survival, both overall and within predefined patient subgroups. Hazard ratios (HRs) for the effects of radiotherapy timing on event-free survival and subgroup interactions were combined using fixed-effect meta-analysis. FINDINGS We identified three eligible trials and were able to obtain updated results for event-free survival for 2153 patients recruited between November, 2007, and December, 2016. Median follow-up ranged from 60 months to 78 months, with a maximum follow-up of 132 months. 1075 patients were randomly assigned to receive adjuvant radiotherapy and 1078 to a policy of early salvage radiotherapy, of whom 421 (39·1%) had commenced treatment at the time of analysis. Patient characteristics were balanced within trials and overall. Median age was similar between trials at 64 or 65 years (with IQRs ranging from 59 to 68 years) across the three trials and most patients (1671 [77·6%]) had a Gleason score of 7. All trials were assessed as having low risk of bias. Based on 270 events, the meta-analysis showed no evidence that event-free survival was improved with adjuvant radiotherapy compared with early salvage radiotherapy (HR 0·95, 95% CI 0·75-1·21; p=0·70), with only a 1 percentage point (95% CI -2 to 3) change in 5-year event-free survival (89% vs 88%). Results were consistent across trials (heterogeneity p=0·18; I2=42%). INTERPRETATION This collaborative and prospectively designed systematic review and meta-analysis suggests that adjuvant radiotherapy does not improve event-free survival in men with localised or locally advanced prostate cancer. Until data on long-term outcomes are available, early salvage treatment would seem the preferable treatment policy as it offers the opportunity to spare many men radiotherapy and its associated side-effects. FUNDING UK Medical Research Council.
Collapse
Affiliation(s)
- Claire L Vale
- MRC Clinical Trials Unit, University College London, London, UK.
| | - David Fisher
- MRC Clinical Trials Unit, University College London, London, UK
| | | | - Christopher Parker
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
| | | | | | | | - Matthew R Sydes
- MRC Clinical Trials Unit, University College London, London, UK
| | | | | | - Chris Brown
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
| | | | - Adrian Cook
- MRC Clinical Trials Unit, University College London, London, UK
| | - Silvia Forcat
- MRC Clinical Trials Unit, University College London, London, UK
| | | | | | | | - Jayne F Tierney
- MRC Clinical Trials Unit, University College London, London, UK
| |
Collapse
|
28
|
You B, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard A, Perren T, Cook A, Pfisterer J, Bois A, Kurzeder C, Burges A, Peron J, Freyer G, Colomban O. Preponderant impact of the chemosensitivity assessed by the modeled CA-125 kinetic parameter KELIM on the success of the first line treatment: Pooled analysis of AGO-OVAR 7, AGO-OVAR 9 and ICON7 trials--a GINECO-GINEGEPS study. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Clamp A, James E, McNeish I, Dean A, Kim JW, O'Donnell D, Hook J, Gallardo-Rincon D, Coyle C, Blagden S, Brenton J, Naik R, Perren T, Sundar S, Cook A, Badrock J, Swart A, Parmar M, Kaplan R, Ledermann J. 805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
30
|
Farmer RE, Daniel R, Ford D, Cook A, Musiime V, Bwakura-Dangarembizi M, Gibb DM, Prendergast AJ, Walker AS. Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy. PLoS One 2020; 15:e0233877. [PMID: 32645021 PMCID: PMC7347189 DOI: 10.1371/journal.pone.0233877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Accepted: 05/13/2020] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND The impact of nutritional supplements on weight gain in HIV-infected children on antiretroviral treatment (ART) remains uncertain. Starting supplements depends upon current weight-for-age or other acute malnutrition indicators, producing time-dependent confounding. However, weight-for-age at ART initiation may affect subsequent weight gain, independent of supplement use. Implications for marginal structural models (MSMs) with inverse probability of treatment weights (IPTW) are unclear. METHODS In the ARROW trial, non-randomised supplement use and weight-for-age were recorded monthly from ART initiation. The effect of supplements on weight-for-age over the first year was estimated using generalised estimating equation MSMs with IPTW, both with and without interaction terms between baseline weight-for-age and time. Separately, data were simulated assuming no supplement effect, with use depending on current weight-for-age, and weight-for-age trajectory depending on baseline weight-for-age to investigate potential bias associated with different MSM specifications. RESULTS In simulations, despite correctly specifying IPTW, omitting an interaction in the MSM between baseline weight-for-age and time produced increasingly biased estimates as associations between baseline weight-for-age and subsequent weight trajectory increased. Estimates were unbiased when the interaction between baseline weight-for-age and time was included, even if the data were simulated with no such interaction. In ARROW, without an interaction the estimated effect was +0.09 (95%CI +0.02,+0.16) greater weight-for-age gain per month's supplement use; this reduced to +0.03 (-0.04,+0.10) including the interaction. DISCUSSION This study highlights a specific situation in which MSM model misspecification can occur and impact the resulting estimate. Since an interaction in the MSM (outcome) model does not bias the estimate of effect if the interaction does not exist, it may be advisable to include such a term when fitting MSMs for repeated measures.
Collapse
Affiliation(s)
- Ruth E. Farmer
- MRC Clinical Trials Unit at UCL, UCL Institute for Clinical Trials and Methodology, London, England, United Kingdom
- Department of Non Communicable Diseases Epidemiology, London School of Hygiene & Tropical Medicine, London, England, United Kingdom
- * E-mail:
| | - Rhian Daniel
- Division of Population Medicine, University of Cardiff, Cardiff, Wales, United Kingdom
| | - Deborah Ford
- MRC Clinical Trials Unit at UCL, UCL Institute for Clinical Trials and Methodology, London, England, United Kingdom
| | - Adrian Cook
- MRC Clinical Trials Unit at UCL, UCL Institute for Clinical Trials and Methodology, London, England, United Kingdom
| | - Victor Musiime
- Joint Clinical Research Center, Kampala, Uganda
- Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda
| | | | - Diana M. Gibb
- MRC Clinical Trials Unit at UCL, UCL Institute for Clinical Trials and Methodology, London, England, United Kingdom
| | | | - A. Sarah Walker
- MRC Clinical Trials Unit at UCL, UCL Institute for Clinical Trials and Methodology, London, England, United Kingdom
| | | |
Collapse
|
31
|
Ali A, Hoyle AP, Parker CC, Brawley CD, Cook A, Amos C, Calvert J, Douis H, Mason MD, Attard G, Parmar MKB, Sydes MR, James ND, Clarke NW. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison". Eur Urol Oncol 2020; 3:412-419. [PMID: 32591246 PMCID: PMC7443695 DOI: 10.1016/j.euo.2020.05.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 04/25/2020] [Accepted: 05/06/2020] [Indexed: 01/21/2023]
Abstract
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone metastases is limited by interobserver variations, and it does not account for metastasis volume or lesional coalescence. The automated bone scan index (aBSI) is a quantitative method of evaluating bone metastatic burden in a standardised and reproducible manner. Objective To evaluate whether aBSI has utility as a predictive imaging biomarker to define a newly diagnosed metastatic prostate cancer population that might benefit from the addition of prostate RT to standard of care (SOC) systemic therapy. Design, setting, and participants This is an exploratory analysis of men with newly diagnosed metastatic prostate cancer randomised in a 1:1 ratio to either SOC or SOC + prostate RT within the STAMPEDE “M1|RT comparison”. Intervention The SOC was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December 2015. Men allocated RT received either a daily or a weekly schedule that was nominated before randomisation. Outcome measurements and statistical analysis Baseline bone scans were evaluated retrospectively to calculate aBSI. We used overall (OS) and failure-free (FFS) survival as the end points. Treatment-aBSI interaction was evaluated using the multivariable fractional polynomial interaction (MFPI) and subpopulation treatment effect pattern plot. Further analysis was done in aBSI quartiles using Cox regression models adjusted for stratification factors. Results and limitations : Baseline bone scans for 660 (SOC: 323 and SOC + RT: 337) of 2061 men randomised within the “M1|RT comparison” met the software requirements for aBSI calculation. The median age was 68 yr, median PSA was 100 ng/mL, median aBSI was 0.9, and median follow-up was 39 mo. Baseline patient characteristics including aBSI were balanced between the treatment groups. Using the MFPI procedure, there was evidence of aBSI-treatment interaction for OS (p = 0.04, MFPI procedure) and FFS (p < 0.01, MFPI procedure). Graphical evaluation of estimated treatment effect plots showed that the OS and FFS benefit from prostate RT was greatest in patients with a low aBSI. Further analysis in quartiles based on aBSI supported this finding. Conclusions A low automated bone scan index is predictive of survival benefit associated with prostate RT in men with newly diagnosed metastatic prostate cancer. Patient summary The widely used bone scan can be evaluated using an automated technique to potentially select men with newly diagnosed metastatic prostate cancer who might benefit from prostate radiotherapy.
Collapse
Affiliation(s)
- Adnan Ali
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, UK; FASTMAN Centre of Prostate Cancer Excellence, Manchester Cancer Research Centre, Manchester, UK; Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK
| | - Alex P Hoyle
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, UK; FASTMAN Centre of Prostate Cancer Excellence, Manchester Cancer Research Centre, Manchester, UK; Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK; Department of Urology, The Salford NHS Foundation Trust, Manchester, UK
| | | | - Christopher D Brawley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Adrian Cook
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Claire Amos
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Joanna Calvert
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Hassan Douis
- Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | | | | | - Mahesh K B Parmar
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Matthew R Sydes
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Nicholas D James
- Royal Marsden Hospital and The Institute of Cancer Research, London, UK
| | - Noel W Clarke
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, UK; FASTMAN Centre of Prostate Cancer Excellence, Manchester Cancer Research Centre, Manchester, UK; Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK; Department of Urology, The Salford NHS Foundation Trust, Manchester, UK.
| | | |
Collapse
|
32
|
Reventun P, Sanchez-Esteban S, Cook A, Cuadrado I, Roza C, Moreno-Gomez-Toledano R, Muñoz C, Zaragoza C, Bosch RJ, Saura M. Bisphenol A induces coronary endothelial cell necroptosis by activating RIP3/CamKII dependent pathway. Sci Rep 2020; 10:4190. [PMID: 32144343 PMCID: PMC7060177 DOI: 10.1038/s41598-020-61014-1] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Accepted: 02/20/2020] [Indexed: 02/07/2023] Open
Abstract
Epidemiological studies link long term exposure to xenoestrogen Bisphenol-A to adverse cardiovascular effects. Our previous results show that BPA induces hypertension by a mechanism involving CamKII activation and increased redox stress caused by eNOS uncoupling. Recently, CamKII sustained activation has been recognized as a central mediator of programmed cell death in cardiovascular diseases, including necroptosis. However, the role of necroptosis in cardiac response to BPA had not yet been explored. Mice exposed to BPA for 16 weeks showed altered heart function, electrical conduction, and increased blood pressure. Besides, a stress test showed ST-segment depression, indicative of cardiac ischemia. The hearts exhibited cardiac hypertrophy and reduced vascularization, interstitial edema, and large hemorrhagic foci accompanied by fibrinogen deposits. BPA initiated a cardiac inflammatory response, up-regulation of M1 macrophage polarization, and increased oxidative stress, coinciding with the increased expression of CamKII and the necroptotic effector RIP3. In addition, cell death was especially evident in coronary endothelial cells within hemorrhagic areas, and Evans blue extravasation indicated a vascular leak in response to Bisphenol-A. Consistent with the in vivo findings, BPA increased the necroptosis/apoptosis ratio, the expression of RIP3, and CamKII activation in endothelial cells. Necrostatin-1, an inhibitor of necroptosis, alleviated BPA induced cardiac dysfunction and prevented the inflammatory and hemorrhagic response in mice. Mechanistically, silencing of RIP3 reversed BPA-induced necroptosis and CamKII activation in endothelial cells, while inhibition of CamKII activation by KN-93 had no effect on RIP3 expression but decreased necroptotic cell death suggesting that BPA induced necroptosis is mediated by a RIP 3/CamKII dependent pathway. Our results reveal a novel pathogenic role of BPA on the coronary circulation. BPA induces endothelial cell necroptosis, promotes the weakening of coronary vascular wall, which caused internal ventricular hemorrhages, delaying the reparative process and ultimately leading to cardiac dysfunction.
Collapse
Affiliation(s)
- P Reventun
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | | | - A Cook
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | - I Cuadrado
- Pharmacology, Pharmacognosy and Botanics Dpt, Complutense University (UCM), Madrid, Spain
| | - C Roza
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | | | - C Muñoz
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | - C Zaragoza
- Joint Unit of Cardiovascular Research University Francisco de Vitoria and Hospital Ramon y Cajal, Madrid, Spain
| | - R J Bosch
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | - M Saura
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain.
| |
Collapse
|
33
|
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley DP, Douis H, Gilbert D, Gillessen S, Jones RJ, Langley RE, MacNair A, Malik Z, Mason MD, Matheson D, Millman R, Parker CC, Ritchie AWS, Rush H, Russell JM, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan JM, Parikh O, Protheroe A, Rudman S, Srihari NN, Simms M, Tanguay JS, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes MR, Parmar MKB, James ND. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol 2020; 31:442. [PMID: 32067690 PMCID: PMC8929236 DOI: 10.1016/j.annonc.2020.01.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
- N W Clarke
- Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester.
| | - A Ali
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester
| | - F C Ingleby
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London; London School of Hygiene and Tropical Medicine, London
| | - A Hoyle
- Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester
| | - C L Amos
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | | | - C D Brawley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - J Calvert
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - S Chowdhury
- Guy's and Saint Thomas' NHS Foundation Trust, London
| | - A Cook
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - W Cross
- St James University Hospital, Leeds
| | | | - H Douis
- Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham
| | - D Gilbert
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - S Gillessen
- Division of Cancer Sciences, The University of Manchester, Manchester
| | - R J Jones
- Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow
| | - R E Langley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - A MacNair
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - Z Malik
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | | | - D Matheson
- Faculty of Education Health and Wellbeing, University of Wolverhampton, Wolverhampton
| | - R Millman
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - C C Parker
- Institute of Cancer Research, Sutton-London; RoyalMarsden NHS Foundation Trust, London
| | - A W S Ritchie
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - H Rush
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - J M Russell
- Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre, Glasgow
| | - J Brown
- University of Sheffield, Sheffield
| | | | - A Birtle
- Lancashire Teaching Hospitals NHS Foundation Trust, Preston
| | - L Capaldi
- Worcestershire Acute Hospitals NHS Trust, Worcester
| | - J Gale
- Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth
| | | | - A Lydon
- Torbay and South Devon NHS Foundation Trust, Torbay
| | | | - A Omlin
- Department of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland
| | - J M O'Sullivan
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK
| | - O Parikh
- East Lancashire Hospitals NHS Trust, Blackburn, UK
| | - A Protheroe
- Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - S Rudman
- Guy's and Saint Thomas' NHS Foundation Trust, London
| | - N N Srihari
- Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK
| | - M Simms
- Hull and East Yorkshire Hospitals NHS Trust, Hull, UK
| | | | - S Tolan
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - J Wagstaff
- Swansea University College of Medicine, Swansea, UK
| | - J Wallace
- Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow
| | - J Wylie
- The Christie NHS Foundation Trust, Manchester, UK
| | - A Zarkar
- Heartlands Hospital, Birmingham, UK
| | - M R Sydes
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - M K B Parmar
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - N D James
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| |
Collapse
|
34
|
Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2020; 3:e1918939. [PMID: 31922558 PMCID: PMC6991254 DOI: 10.1001/jamanetworkopen.2019.18939] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 10/21/2019] [Indexed: 11/20/2022] Open
Abstract
Importance The Gynecologic Cancer InterGroup (GCIG) recommended that progression-free survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced ovarian cancer. Evidence is lacking for the validity of PFS as a surrogate marker of OS in the modern era of different treatment types. Objective To evaluate whether PFS is a surrogate end point for OS in patients with advanced ovarian cancer. Data Sources In September 2016, a comprehensive search of publications in MEDLINE was conducted for randomized clinical trials of systematic treatment in patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer. The GCIG groups were also queried for potentially completed but unpublished trials. Study Selection Studies with a minimum sample size of 60 patients published since 2001 with PFS and OS rates available were eligible. Investigational treatments considered included initial, maintenance, and intensification therapy consisting of agents delivered at a higher dose and/or frequency compared with that in the control arm. Data Extraction and Synthesis Using the meta-analytic approach on randomized clinical trials published from January 1, 2001, through September 25, 2016, correlations between PFS and OS at the individual level were estimated using the Kendall τ model; between-treatment effects on PFS and OS at the trial level were estimated using the Plackett copula bivariate (R2) model. Criteria for PFS surrogacy required R2 ≥ 0.80 at the trial level. Analysis was performed from January 7 through March 20, 2019. Main Outcomes and Measures Overall survival and PFS based on measurement of cancer antigen 125 levels confirmed by radiological examination results or by combined GCIG criteria. Results In this meta-analysis of 17 unique randomized trials of standard (n = 7), intensification (n = 5), and maintenance (n = 5) chemotherapies or targeted treatments with data from 11 029 unique patients (median age, 58 years [range, 18-88 years]), a high correlation was found between PFS and OS at the individual level (τ = 0.724; 95% CI, 0.717-0.732), but a low correlation was found at the trial level (R2 = 0.24; 95% CI, 0-0.59). Subgroup analyses led to similar results. In the external validation, 14 of the 16 hazard ratios for OS in the published reports fell within the 95% prediction interval from PFS. Conclusions and Relevance This large meta-analysis of individual patient data did not establish PFS as a surrogate end point for OS in first-line treatment of advanced ovarian cancer, but the analysis was limited by the narrow range of treatment effects observed or by poststudy treatment. These results suggest that if PFS is chosen as a primary end point, OS must be measured as a secondary end point.
Collapse
Affiliation(s)
- Xavier Paoletti
- Groupe d’investigateurs national des Etudes des Cancers Ovariens (GINECO), Paris, France
- Gustave Roussy Cancer Center and Institut National de la Santé et de la Recherche Medicale Oncostat, Villejuif, France
- Department of Biostatistics, University of Versailles St Quentin, Institut Curie, Saint-Cloud, France
| | - Liz-Anne Lewsley
- Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research United Kingdom Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Gennaro Daniele
- Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Clinical Trials Unit, Istituto Nazionale Tumori– Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli, Italia
| | - Adrian Cook
- Medical Research Counsel Clinical Trials Unit, University College London, London, United Kingdom
| | - Nozomu Yanaihara
- Japanese Gynecologic Oncology Group (JGOG), Jikei University School of Medicine, Tokyo, Japan
| | - Anna Tinker
- Canadian Cancer Trials Group (CCTG), University of British Columbia, Vancouver, British Columbia, Canada
| | - Gunnar Kristensen
- Nordic Society of Gynaecological Oncology, Norwegian Radium Hospital, Oslo, Norway
| | - Petronella B. Ottevanger
- European Organisation for Research and Treatment of Cancer, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Gerasimos Aravantinos
- Hellenic Cooperative Oncology Group, General Oncology Hospital of Kifissia, Nea Kifissia, Greece
| | - Austin Miller
- Gynecologic Oncology Group (GOG), Roswell Park Comprehensive Cancer Center, Buffalo, New York
| | - Ingrid A. Boere
- Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands
| | - Robert Fruscio
- University of Milan Bicocca, San Gerardo Hospital, Monza, Italy
| | - Anna K. L. Reyners
- University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Eric Pujade-Lauraine
- Association de Recherche sur les Cancers dont Gynécologiques–GINECO, Université Paris Descartes, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Andrea Harkin
- Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research United Kingdom Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Sandro Pignata
- MITO, Istituto Nazionale Tumori di Napoli IRCCS Fondazione G Pascale, Napoli, Italy
| | - Tatsuo Kagimura
- JGOG, Foundation for Biomedical Research and Innovation at Kobe, Translational Research Center for Medical Innovation, Kobe, Japan
| | - Stephen Welch
- CCTG, London Health Sciences Centre, London, Ontario, Canada
| | - James Paul
- Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research United Kingdom Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | | | - Rosalind M. Glasspool
- SGCTG, Beatson West of Scotland Cancer Centre, NHS (National Health Service) Greater Glasgow and Clyde, Glasgow, United Kingdom
| |
Collapse
|
35
|
Abstract
Abstract
Funding Acknowledgements
La Fondation Dassault Systèmes, British Heart Foundation
Background
Virtual reality (VR) provides a unique possibility to interact with three-dimensional objects. Still in its infancy, the integration of VR with advanced cardiovascular imaging technology allows users to handle patient-specific cardiac models.
Purpose
The purpose of this study was to evaluate the potential role of VR in teaching cardiac morphology of congenital heart diseases to healthcare professionals.
Methods
From October 2018 to April 2019, a VR application was developed in-house and incorporated within the Cardiac Morphology courses run monthly at our centre. The VR software included patient-specific 3D models which were reconstructed from 3D imaging datasets (micro-CT, CT, CMR or 3D echo data). The most important cardiac structures were labelled to allow easier identification of anatomical features (Figure 1). Each participant had the possibility to evaluate 6 different patient specific models including: a foetal normal heart, a foetal Transposition of the Great Arteries, a foetal Atrioventricular septal defect, a four-month-old Tetralogy of Fallot, a four-month-old Double Outlet Right Ventricle with uncommitted ventricular septal defect and a one-year-old Patent Ductus Arteriosus. All the attendees could evaluate the models individually for 5 to 15 minutes. A short survey with six questions was administered at the end of the session. The survey included sections asking for professional background information, prior VR experience and feedback on the VR experience which was assessed with a 5 points Likert-type scale (from 1 to 5).
Results
The VR session was attended by 20 delegates with mixed professional backgrounds including cardiac surgeons, cardiologists, cardiac anaesthesiologists, paediatricians, pathologists and medical students. Only 2 out of 20 had tried a virtual reality application before, although neither of those prior VR experiences had a medical focus. The VR application was considered ‘’extremely helpful’’ (5/5) in understanding the anatomy by 44% of participants, and ‘’very helpful’’(4/5) by another 44%. The methods of interaction (e.g. grabbing objects, using a cutting tool) were considered "extremely intuitive’’ (5/5) by 72% of attendees, and "very intuitive"(4/5) by 27%. In 94% of the cases, the attendees responded to be "very willing"(4/5) or "extremely willing"(5/5) to implement a VR setup at their own institutions for the purpose of evaluating cardiac anatomies.
Conclusion
The use of the VR station in cardiac morphology courses was very well received by the attendees, as it is frequently considered easy to use and very helpful in aiding the understanding of congenital heart diseases. The survey highlighted a great potential for implementing this tool in educational programmes.
Abstract P369 Figure 1
Collapse
Affiliation(s)
- E G Milano
- University College London, London, United Kingdom of Great Britain & Northern Ireland
| | - E Pajaziti
- University College London, London, United Kingdom of Great Britain & Northern Ireland
| | - S Schievano
- University College London, London, United Kingdom of Great Britain & Northern Ireland
| | - A Cook
- University College London, London, United Kingdom of Great Britain & Northern Ireland
| | - C Capelli
- University College London, London, United Kingdom of Great Britain & Northern Ireland
| |
Collapse
|
36
|
Haidari G, Day S, Wood M, Ridgers H, Cope AV, Fleck S, Yan C, Reijonen K, Hannaman D, Spentzou A, Hayes P, Vogt A, Combadiere B, Cook A, McCormack S, Shattock RJ. The Safety and Immunogenicity of GTU ®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART. Front Immunol 2019; 10:2911. [PMID: 31921170 PMCID: PMC6923267 DOI: 10.3389/fimmu.2019.02911] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Accepted: 11/27/2019] [Indexed: 12/25/2022] Open
Abstract
Previous studies have shown targeting different tissues via the transcutaneous (TC) and intramuscular injection (IM) with or without electroporation (EP) has the potential to trigger immune responses to DNA vaccination. The CUTHIVTHER 001 Phase I/II randomized controlled clinical trial was designed to determine whether the mode of DNA vaccination delivery (TC+IM or EP+IM) could influence the quality and function of induced cellular immune responses compared to placebo, in an HIV positive clade B cohort on antiretroviral therapy (ART). The GTU®MultiHIV B DNA vaccine DNA vaccine encoded a MultiHIV B clade fusion protein to target the cellular response. Overall the vaccine and regimens were safe and well-tolerated. There were robust pre-vaccination IFN-γ responses with no measurable change following vaccination compared to placebo. However, modest intracellular cytokine staining (ICS) responses were seen in the TC+IM group. A high proportion of individuals demonstrated potent viral inhibition at baseline that was not improved by vaccination. These results show that HIV positive subjects with nadir CD4+ counts ≥250 on suppressive ART display potent levels of cellular immunity and viral inhibition, and that DNA vaccination alone is insufficient to improve such responses. These data suggest that more potent prime-boost vaccination strategies are likely needed to improve pre-existing responses in similar HIV-1 cohorts (This study has been registered at http://ClinicalTrials.gov under registration no. NCT02457689).
Collapse
Affiliation(s)
- G Haidari
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| | - Suzanne Day
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| | - M Wood
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| | - H Ridgers
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| | - Alethea V Cope
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| | - Sue Fleck
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Celine Yan
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| | | | - Drew Hannaman
- Ichor Medical Systems Inc, San Diego, CA, United States
| | - Aggeliki Spentzou
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| | - Peter Hayes
- Human Immunology Laboratory, International AIDS Vaccine Initiative, Imperial College London, London, United Kingdom
| | - A Vogt
- Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Behazine Combadiere
- Sorbonne Université, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), INSERM U1135, Paris, France
| | - Adrian Cook
- Medical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom
| | - Sheena McCormack
- Medical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom
| | - Robin J Shattock
- Group of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom
| |
Collapse
|
37
|
Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol 2019; 76:719-728. [PMID: 31447077 DOI: 10.1016/j.eururo.2019.08.006] [Citation(s) in RCA: 127] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Accepted: 08/07/2019] [Indexed: 12/18/2022]
Abstract
BACKGROUND Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains uncertainty as to whether men with LATITUDE "low-risk" M1 disease benefit from androgen deprivation therapy (ADT) combined with abiraterone acetate and prednisolone (AAP). OBJECTIVE Evaluation of heterogeneity of effect between LATITUDE high- and low-risk M1 prostate cancer patients receiving ADT + AAP in the STAMPEDE trial. DESIGN, SETTING, AND PARTICIPANTS A post hoc subgroup analysis of the 2017 STAMPEDE "abiraterone comparison". Staging scans for M1 patients contemporaneously randomised to ADT or ADT + AAP within the STAMPEDE trial were evaluated centrally and blind to treatment assignment. Stratification was by risk according to the criteria set out in the LATITUDE trial. Exploratory subgroup stratification incorporated the CHAARTED criteria. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary outcome measure was overall survival (OS) and the secondary outcome measure was failure-free survival (FFS). Further exploratory analysis evaluated clinical skeletal-related events, progression-free survival (PFS), and prostate cancer-specific death. Standard Cox-regression and Kaplan-Meier survival estimates were employed for analysis. RESULTS AND LIMITATIONS A total of 901 M1 STAMPEDE patients were evaluated after exclusions. Of the patients, 428 (48%) were identified as having a low risk and 473 (52%) a high risk. Patients receiving ADT + AAP had significantly improved OS (low-risk hazard ratio [HR]: 0.66, 95% confidence interval or CI [0.44-0.98]) and FFS (low-risk HR: 0.24, 95% CI [0.17-0.33]) compared with ADT alone. Heterogeneity of effect was not seen between low- and high-risk groups for OS or FFS. For OS benefit in low risk, the number needed to treat was four times greater than that for high risk. However, this was not observed for the other measured endpoints. CONCLUSIONS Men with mHNPC gain treatment benefit from ADT + AAP irrespective of risk stratification for "risk" or "volume". PATIENT SUMMARY Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.
Collapse
Affiliation(s)
- Alex P Hoyle
- The Christie and Royal Salford Hospitals, Manchester, UK; Genito Urinary Cancer Research Group and the FASTMAN Centre of Excellence, Division of Cancer Sciences, The University of Manchester, Manchester, UK
| | - Adnan Ali
- The Christie and Royal Salford Hospitals, Manchester, UK
| | - Nicholas D James
- Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK
| | - Adrian Cook
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | | | | | | | | | | | | | - Christopher D Brawley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Clare Gilson
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | | | - Silke Gillessen
- Division of Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Christie Hospital, Manchester, UK; University of Manchester, Manchester, UK; Swiss Group for Cancer Clinical Research (SAKK), Bern, Switzerland
| | | | - Rob J Jones
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK
| | | | | | | | | | - Martin Russell
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK
| | - Hassan Douis
- Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK
| | - Mahesh K B Parmar
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Matthew R Sydes
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK
| | - Noel W Clarke
- The Christie and Royal Salford Hospitals, Manchester, UK; Genito Urinary Cancer Research Group and the FASTMAN Centre of Excellence, Division of Cancer Sciences, The University of Manchester, Manchester, UK.
| |
Collapse
|
38
|
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley DP, Douis H, Gilbert D, Gillessen S, Jones RJ, Langley RE, MacNair A, Malik Z, Mason MD, Matheson D, Millman R, Parker CC, Ritchie AWS, Rush H, Russell JM, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan JM, Parikh O, Protheroe A, Rudman S, Srihari NN, Simms M, Tanguay JS, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes MR, Parmar MKB, James ND. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019; 30:1992-2003. [PMID: 31560068 PMCID: PMC6938598 DOI: 10.1093/annonc/mdz396] [Citation(s) in RCA: 222] [Impact Index Per Article: 44.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHODS We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. RESULTS Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). CONCLUSIONS The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.
Collapse
Affiliation(s)
- N W Clarke
- Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester.
| | - A Ali
- Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester
| | - F C Ingleby
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London; London School of Hygiene and Tropical Medicine, London
| | - A Hoyle
- Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester
| | - C L Amos
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | | | - C D Brawley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - J Calvert
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - S Chowdhury
- Guy's and Saint Thomas' NHS Foundation Trust, London
| | - A Cook
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - W Cross
- St James University Hospital, Leeds
| | | | - H Douis
- Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham
| | - D Gilbert
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - S Gillessen
- Division of Cancer Sciences, The University of Manchester, Manchester
| | - R J Jones
- Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow
| | - R E Langley
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - A MacNair
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - Z Malik
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | | | - D Matheson
- Faculty of Education Health and Wellbeing, University of Wolverhampton, Wolverhampton
| | - R Millman
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - C C Parker
- Institute of Cancer Research, Sutton-London; Royal Marsden NHS Foundation Trust, London
| | - A W S Ritchie
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - H Rush
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - J M Russell
- Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre, Glasgow
| | - J Brown
- University of Sheffield, Sheffield
| | | | - A Birtle
- Lancashire Teaching Hospitals NHS Foundation Trust, Preston
| | - L Capaldi
- Worcestershire Acute Hospitals NHS Trust, Worcester
| | - J Gale
- Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth
| | | | - A Lydon
- Torbay and South Devon NHS Foundation Trust, Torbay
| | | | - A Omlin
- Department of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland
| | - J M O'Sullivan
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast
| | - O Parikh
- East Lancashire Hospitals NHS Trust, Blackburn
| | - A Protheroe
- Oxford University Hospitals NHS Foundation Trust, Oxford
| | - S Rudman
- Guy's and Saint Thomas' NHS Foundation Trust, London
| | - N N Srihari
- Shrewsbury and Telford Hospital NHS Trust, Shrewsbury
| | - M Simms
- Hull and East Yorkshire Hospitals NHS Trust, Hull
| | | | - S Tolan
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - J Wagstaff
- Swansea University College of Medicine, Swansea
| | - J Wallace
- Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow
| | - J Wylie
- The Christie NHS Foundation Trust, Manchester
| | | | - M R Sydes
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - M K B Parmar
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London
| | - N D James
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham
| |
Collapse
|
39
|
Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, Shaw LP, Abongomera G, Musiime V, Cook A, Brown JR, Brooks A, Owen-Powell E, Gibb DM, Prendergast AJ, Sarah Walker A, Thiebaut R, Klein N. Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV. J Infect Dis 2019; 219:89-100. [PMID: 30107546 PMCID: PMC6284549 DOI: 10.1093/infdis/jiy495] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 08/10/2018] [Indexed: 12/12/2022] Open
Abstract
Objective Immune activation is associated with morbidity and mortality during human immunodeficiency virus (HIV) infection, despite receipt of antiretroviral therapy (ART). We investigated whether microbial translocation drives immune activation in HIV-infected Ugandan children. Methods Nineteen markers of immune activation and inflammation were measured over 96 weeks in HIV-infected Ugandan children in the CHAPAS-3 Trial and HIV-uninfected age-matched controls. Microbial translocation was assessed using molecular techniques, including next-generation sequencing. Results Of 249 children included, 142 were infected with HIV; of these, 120 were ART naive, with a median age of 2.8 years (interquartile range [IQR], 1.7–4.0 years) and a median baseline CD4+ T-cell percentage of 20% (IQR, 14%–24%), and 22 were ART experienced, with a median age of 6.5 years (IQR, 5.9–9.2 years) and a median baseline CD4+ T-cell percentage of 35% (IQR, 31%–39%). The control group comprised 107 children without HIV infection. The median increase in the CD4+ T-cell percentage was 17 percentage points (IQR, 12–22 percentage points) at week 96 among ART-naive children, and the viral load was <100 copies/mL in 76% of ART-naive children and 91% of ART-experienced children. Immune activation decreased with ART use. Children could be divided on the basis of immune activation markers into the following 3 clusters: in cluster 1, the majority of children were HIV uninfected; cluster 2 comprised a mix of HIV-uninfected children and HIV-infected ART-naive or ART-experienced children; and in cluster 3, the majority were ART naive. Immune activation was low in cluster 1, decreased in cluster 3, and persisted in cluster 2. Blood microbial DNA levels were negative or very low across groups, with no difference between clusters except for Enterobacteriaceae organisms (the level was higher in cluster 1; P < .0001). Conclusion Immune activation decreased with ART use, with marker clustering indicating different activation patterns according to HIV and ART status. Levels of bacterial DNA in blood were low regardless of HIV status, ART status, and immune activation status. Microbial translocation did not drive immune activation in this setting. Clinical Trials Registration ISRCTN69078957.
Collapse
Affiliation(s)
| | - Edouard Lhomme
- INSERM, Bordeaux Population Health Research Centre, UMR 1219, University of Bordeaux, ISPED.,Statistics in System Biology and Translational Medicine (SISTM Team), INRIA Research Centre.,Vaccine Research Institute (VRI), Créteil, France
| | - Kathryn Harris
- Microbiology, Virology, and Infection Prevention and Control, Camelia Botnar Laboratories, GOS National Health Service Foundation Trust
| | - Julia Kenny
- Infection, Immunity, and Inflammation Programme
| | - Ronan Doyle
- Microbiology, Virology, and Infection Prevention and Control, Camelia Botnar Laboratories, GOS National Health Service Foundation Trust
| | | | - Liam P Shaw
- Infection, Immunity, and Inflammation Programme
| | | | | | - Adrian Cook
- Medical Research Council Clinical Trials Unit at UCL
| | - Julianne R Brown
- Microbiology, Virology, and Infection Prevention and Control, Camelia Botnar Laboratories, GOS National Health Service Foundation Trust
| | - Anthony Brooks
- University College London (UCL) Genomics, UCL Great Ormond Street (GOS) Institute of Child Health
| | | | - Diana M Gibb
- Medical Research Council Clinical Trials Unit at UCL
| | - Andrew J Prendergast
- Blizard Institute, Queen Mary University of London, London, United Kingdom.,Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe
| | | | - Rodolphe Thiebaut
- INSERM, Bordeaux Population Health Research Centre, UMR 1219, University of Bordeaux, ISPED.,Statistics in System Biology and Translational Medicine (SISTM Team), INRIA Research Centre.,Vaccine Research Institute (VRI), Créteil, France
| | - Nigel Klein
- Infection, Immunity, and Inflammation Programme
| | | |
Collapse
|
40
|
Parker C, Clarke N, Cook A, Kynaston H, Meidahl Petersen P, Cross W, Persad R, Catton C, Logue J, Payne H, Saad F, Brasso K, Lindberg H, Zarkar A, Raman R, Roder M, Heath C, Parulekar W, Parmar M, Sydes M. Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.042] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Tryliskyy Y, Lai G, Ghimire N, Sobczak E, Mackenzie S, Cook A, Mlotshwa M. The appropriateness of MRCP requests in investigation of suspected common bile duct stones. Clin Radiol 2019. [DOI: 10.1016/j.crad.2019.09.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Vale C, Brihoum M, Chabaud S, Cook A, Fisher D, Forcat S, Fraser-Browne C, Herschtal A, Kneebone A, Nénan S, Parker C, Parmar M, Pearse M, Richaud P, Rogozińska E, Sargos P, Sydes M, Tierney J. Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.041] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Hum Gene Ther 2019; 29:1011-1028. [PMID: 30027768 PMCID: PMC6214652 DOI: 10.1089/hum.2018.075] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Intradermal (i.d.) and intramuscular (i.m.) injections when administered with or without electroporation (EP) have the potential to tailor the immune response to DNA vaccination. This Phase I randomized controlled clinical trial in human immunodeficiency virus type 1–negative volunteers investigated whether the site and mode of DNA vaccination influences the quality of induced cellular and humoral immune responses following the DNA priming phase and subsequent protein boost with recombinant clade C CN54 gp140. A strategy of concurrent i.d. and i.m. DNA immunizations administered with or without EP was adopted. Subtle differences were observed in the shaping of vaccine-induced virus-specific CD4+ and CD8+ T cell–mediated immune responses between groups receiving: i.d.EP + i.m., i.d. + i.m.EP, and i.d.EP + i.m.EP regimens. The DNA priming phase induced 100% seroconversion in all of the groups. A single, non-adjuvanted protein boost induced a rapid and profound increase in binding antibodies in all groups, with a trend for higher responses in i.d.EP + i.m.EP. The magnitude of antigen-specific binding immunoglobulin G correlated with neutralization of closely matched clade C 93MW965 virus and Fc-dimer receptor binding (FcγRIIa and FcγRIIIa). These results offer new perspectives on the use of combined skin and muscle DNA immunization in priming humoral and cellular responses to recombinant protein.
Collapse
Affiliation(s)
- Hannah Mary Cheeseman
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Suzanne Day
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Leon Robert McFarlane
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Sue Fleck
- 2 Medical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Aleisha Miller
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Tom Cole
- 3 Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Nelson Sousa-Santos
- 3 Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Alethea Cope
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Deniz Cizmeci
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Monica Tolazzi
- 4 Viral Evolution and Transmission Unit, Division of Immunology, Transplant and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Edith Hwekwete
- 3 Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Drew Hannaman
- 5 Ichor Medical Systems, Inc., San Diego, California; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Sven Kratochvil
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Paul Francis McKay
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Amy W Chung
- 6 Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, and UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Stephen J Kent
- 6 Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, and UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France .,7 ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, Australia; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France .,8 Melbourne Sexual Health Centre, Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University , Melbourne, Australia; and UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Adrian Cook
- 2 Medical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Gabriella Scarlatti
- 4 Viral Evolution and Transmission Unit, Division of Immunology, Transplant and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Sonya Abraham
- 3 Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Behazine Combadiere
- 9 Sorbonne Universités, UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Sheena McCormack
- 2 Medical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - David John Lewis
- 3 Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Robin John Shattock
- 1 Department of Medicine, Section of Virology, Group of Mucosal Infection and Immunity, Imperial College London, London, United Kingdom; UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| |
Collapse
|
44
|
Milano EG, Pajaziti E, Sauvage E, Taylor AM, Marek J, Mortensen K, Cook A, Schievano S, Kostolny M, Capelli C. P358Taking surgery out of reality: a repair of double outlet right ventricle planned by means of virtual reality. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez109.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- E G Milano
- University College London, Institute of Cardiovascular Science, LONDON, United Kingdom of Great Britain & Northern Ireland
| | - E Pajaziti
- University College London, Institute of Cardiovascular Science, LONDON, United Kingdom of Great Britain & Northern Ireland
| | - E Sauvage
- University College London, Institute of Cardiovascular Science, LONDON, United Kingdom of Great Britain & Northern Ireland
| | - A M Taylor
- University College London, Institute of Cardiovascular Science, LONDON, United Kingdom of Great Britain & Northern Ireland
| | - J Marek
- Great Ormond Street Hospital for Children, London, United Kingdom of Great Britain & Northern Ireland
| | - K Mortensen
- Great Ormond Street Hospital for Children, London, United Kingdom of Great Britain & Northern Ireland
| | - A Cook
- University College London, Institute of Cardiovascular Science, LONDON, United Kingdom of Great Britain & Northern Ireland
| | - S Schievano
- University College London, Institute of Cardiovascular Science, LONDON, United Kingdom of Great Britain & Northern Ireland
| | - M Kostolny
- Great Ormond Street Hospital for Children, London, United Kingdom of Great Britain & Northern Ireland
| | - C Capelli
- University College London, Institute of Cardiovascular Science, LONDON, United Kingdom of Great Britain & Northern Ireland
| |
Collapse
|
45
|
Karamouza E, Glasspool R, Cook A, Paoletti X. Valeur pronostique de la dynamique du CA125 sur la survie des femmes ayant un cancer des ovaires nouvellement diagnostiqué. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
46
|
Drewnowski A, Arterburn D, Zane J, Aggarwal A, Gupta S, Hurvitz P, Moudon A, Bobb J, Cook A, Lozano P, Rosenberg D. The Moving to Health (M2H) approach to natural experiment research: A paradigm shift for studies on built environment and health. SSM Popul Health 2019; 7:100345. [PMID: 30656207 PMCID: PMC6329830 DOI: 10.1016/j.ssmph.2018.100345] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 12/22/2018] [Accepted: 12/26/2018] [Indexed: 12/02/2022] Open
Abstract
Improving the built environment (BE) is viewed as one strategy to improve community diets and health. The present goal is to review the literature on the effects of BE on health, highlight its limitations, and explore the growing use of natural experiments in BE research, such as the advent of new supermarkets, revitalized parks, or new transportation systems. Based on recent studies on movers, a paradigm shift in built-environment health research may be imminent. Following the classic Moving to Opportunity study in the US, the present Moving to Health (M2H) strategy takes advantage of the fact that changing residential location can entail overnight changes in multiple BE variables. The necessary conditions for applying the M2H strategy to Geographic Information Systems (GIS) databases and to large longitudinal cohorts are outlined below. Also outlined are significant limitations of this approach, including the use of electronic medical records in lieu of survey data. The key research question is whether documented changes in BE exposure can be linked to changes in health outcomes in a causal manner. The use of geo-localized clinical information from regional health care systems should permit new insights into the social and environmental determinants of health.
Collapse
Affiliation(s)
- A. Drewnowski
- Center for Public Health Nutrition, 305 Raitt Hall, #353410, University of Washington, Seattle, WA 98195-03410, USA
| | - D. Arterburn
- Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave. Suite 1600, Seattle, WA 98101, USA
| | - J. Zane
- Center for Public Health Nutrition, 305 Raitt Hall, #353410, University of Washington, Seattle, WA 98195-03410, USA
| | - A. Aggarwal
- Center for Public Health Nutrition, 305 Raitt Hall, #353410, University of Washington, Seattle, WA 98195-03410, USA
| | - S. Gupta
- Center for Public Health Nutrition, 305 Raitt Hall, #353410, University of Washington, Seattle, WA 98195-03410, USA
| | - P.M. Hurvitz
- Urban Form Lab, Department of Urban Design and Planning, College of Built Environments, University of Washington, 1107 NE 45th Street, Suite 535, Seattle, WA 98195-4802, USA
| | - A.V. Moudon
- Urban Form Lab, Department of Urban Design and Planning, College of Built Environments, University of Washington, 1107 NE 45th Street, Suite 535, Seattle, WA 98195-4802, USA
| | - J. Bobb
- Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave. Suite 1600, Seattle, WA 98101, USA
| | - A. Cook
- Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave. Suite 1600, Seattle, WA 98101, USA
| | - P. Lozano
- Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave. Suite 1600, Seattle, WA 98101, USA
| | - D. Rosenberg
- Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave. Suite 1600, Seattle, WA 98101, USA
| |
Collapse
|
47
|
Blagden S, Bertelli G, Frangou E, Butcher C, Love S, Mackean M, Glasspool R, Cook A, Nicum S, Lord R, Ferguson M, Roux R, Martinez M, Black S, James A, Palmer H, Hughes S, Marriott C, Howells L. OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Cook A. C - 03Comparing Performance on the Rey Complex Figure Test Between Hispanics and Non-Hispanics. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Horio M, Hauser K, Sassa Y, Mingazheva Z, Sutter D, Kramer K, Cook A, Nocerino E, Forslund OK, Tjernberg O, Kobayashi M, Chikina A, Schröter NBM, Krieger JA, Schmitt T, Strocov VN, Pyon S, Takayama T, Takagi H, Lipscombe OJ, Hayden SM, Ishikado M, Eisaki H, Neupert T, Månsson M, Matt CE, Chang J. Three-Dimensional Fermi Surface of Overdoped La-Based Cuprates. Phys Rev Lett 2018; 121:077004. [PMID: 30169083 DOI: 10.1103/physrevlett.121.077004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Indexed: 06/08/2023]
Abstract
We present a soft x-ray angle-resolved photoemission spectroscopy study of overdoped high-temperature superconductors. In-plane and out-of-plane components of the Fermi surface are mapped by varying the photoemission angle and the incident photon energy. No k_{z} dispersion is observed along the nodal direction, whereas a significant antinodal k_{z} dispersion is identified for La-based cuprates. Based on a tight-binding parametrization, we discuss the implications for the density of states near the van Hove singularity. Our results suggest that the large electronic specific heat found in overdoped La_{2-x}Sr_{x}CuO_{4} cannot be assigned to the van Hove singularity alone. We therefore propose quantum criticality induced by a collapsing pseudogap phase as a plausible explanation for observed enhancement of electronic specific heat.
Collapse
Affiliation(s)
- M Horio
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - K Hauser
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - Y Sassa
- Department of Physics and Astronomy, Uppsala University, SE-75121 Uppsala, Sweden
| | - Z Mingazheva
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - D Sutter
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - K Kramer
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - A Cook
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - E Nocerino
- Department of Applied Physics, KTH Royal Institute of Technology, Electrum 229, SE-16440 Stockholm Kista, Sweden
| | - O K Forslund
- Department of Applied Physics, KTH Royal Institute of Technology, Electrum 229, SE-16440 Stockholm Kista, Sweden
| | - O Tjernberg
- Department of Applied Physics, KTH Royal Institute of Technology, Electrum 229, SE-16440 Stockholm Kista, Sweden
| | - M Kobayashi
- Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - A Chikina
- Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - N B M Schröter
- Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - J A Krieger
- Laboratory for Muon Spin Spectroscopy, Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland
- Laboratorium für Festkörperphysik, ETH Zürich, CH-8093 Zürich, Switzerland
| | - T Schmitt
- Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - V N Strocov
- Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - S Pyon
- Department of Advanced Materials, University of Tokyo, Kashiwa 277-8561, Japan
| | - T Takayama
- Department of Advanced Materials, University of Tokyo, Kashiwa 277-8561, Japan
| | - H Takagi
- Department of Advanced Materials, University of Tokyo, Kashiwa 277-8561, Japan
| | - O J Lipscombe
- H. H. Wills Physics Laboratory, University of Bristol, Bristol BS8 1TL, United Kingdom
| | - S M Hayden
- H. H. Wills Physics Laboratory, University of Bristol, Bristol BS8 1TL, United Kingdom
| | - M Ishikado
- Comprehensive Research Organization for Science and Society (CROSS), Tokai, Ibaraki 319-1106, Japan
| | - H Eisaki
- Electronics and Photonics Research Institute, National Institute of Advanced Industrial Science and Technology, Ibaraki 305-8568, Japan
| | - T Neupert
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - M Månsson
- Department of Applied Physics, KTH Royal Institute of Technology, Electrum 229, SE-16440 Stockholm Kista, Sweden
| | - C E Matt
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
- Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
- Department of Physics, Harvard University, Cambridge, MA 02138, USA
| | - J Chang
- Physik-Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| |
Collapse
|
50
|
Aaij R, Adeva B, Adinolfi M, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Ali S, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amerio S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews JE, Appleby RB, Archilli F, d'Argent P, Arnau Romeu J, Artamonov A, Artuso M, Aslanides E, Atzeni M, Auriemma G, Baalouch M, Babuschkin I, Bachmann S, Back JJ, Badalov A, Baesso C, Baker S, Balagura V, Baldini W, Baranov A, Barlow RJ, Barschel C, Barsuk S, Barter W, Baryshnikov F, Batozskaya V, Battista V, Bay A, Beaucourt L, Beddow J, Bedeschi F, Bediaga I, Beiter A, Bel LJ, Beliy N, Bellee V, Belloli N, Belous K, Belyaev I, Ben-Haim E, Bencivenni G, Benson S, Beranek S, Berezhnoy A, Bernet R, Berninghoff D, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler MO, van Beuzekom M, Bezshyiko I, Bifani S, Billoir P, Birnkraut A, Bizzeti A, Bjørn M, Blake T, Blanc F, Blusk S, Bocci V, Boettcher T, Bondar A, Bondar N, Bordyuzhin I, Borghi S, Borisyak M, Borsato M, Bossu F, Boubdir M, Bowcock TJV, Bowen E, Bozzi C, Braun S, Britton T, Brodzicka J, Brundu D, Buchanan E, Burr C, Bursche A, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calladine R, Calvi M, Calvo Gomez M, Camboni A, Campana P, Campora Perez DH, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carniti P, Carson L, Carvalho Akiba K, Casse G, Cassina L, Cattaneo M, Cavallero G, Cenci R, Chamont D, Charles M, Charpentier P, Chatzikonstantinidis G, Chefdeville M, Chen S, Cheung SF, Chitic SG, Chobanova V, Chrzaszcz M, Chubykin A, Ciambrone P, Cid Vidal X, Ciezarek G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cogan J, Cogneras E, Cogoni V, Cojocariu L, Collins P, Colombo T, Comerma-Montells A, Contu A, Cook A, Coombs G, Coquereau S, Corti G, Corvo M, Costa Sobral CM, Couturier B, Cowan GA, Craik DC, Crocombe A, Cruz Torres M, Currie R, D'Ambrosio C, Da Cunha Marinho F, Dall'Occo E, Dalseno J, Davis A, De Aguiar Francisco O, De Capua S, De Cian M, De Miranda JM, De Paula L, De Serio M, De Simone P, Dean CT, Decamp D, Del Buono L, Dembinski HP, Demmer M, Dendek A, Derkach D, Deschamps O, Dettori F, Dey B, Di Canto A, Di Nezza P, Dijkstra H, Dordei F, Dorigo M, Dosil Suárez A, Douglas L, Dovbnya A, Dreimanis K, Dufour L, Dujany G, Durante P, Dzhelyadin R, Dziewiecki M, Dziurda A, Dzyuba A, Easo S, Ebert M, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Eitschberger U, Ekelhof R, Eklund L, Ely S, Esen S, Evans HM, Evans T, Falabella A, Farley N, Farry S, Fazzini D, Federici L, Ferguson D, Fernandez G, Fernandez Declara P, Fernandez Prieto A, Ferrari F, Ferreira Rodrigues F, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fitzpatrick C, Fiutowski T, Fleuret F, Fohl K, Fontana M, Fontanelli F, Forshaw DC, Forty R, Franco Lima V, Frank M, Frei C, Fu J, Funk W, Furfaro E, Färber C, Gabriel E, Gallas Torreira A, Galli D, Gallorini S, Gambetta S, Gandelman M, Gandini P, Gao Y, Garcia Martin LM, García Pardiñas J, Garra Tico J, Garrido L, Garsed PJ, Gascon D, Gaspar C, Gavardi L, Gazzoni G, Gerick D, Gersabeck E, Gersabeck M, Gershon T, Ghez P, Gianì S, Gibson V, Girard OG, Giubega L, Gizdov K, Gligorov VV, Golubkov D, Golutvin A, Gomes A, Gorelov IV, Gotti C, Govorkova E, Grabowski JP, Graciani Diaz R, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu A, Greim R, Griffith P, Grillo L, Gruber L, Gruberg Cazon BR, Grünberg O, Gushchin E, Guz Y, Gys T, Göbel C, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haines SC, Hamilton B, Han X, Hancock TH, Hansmann-Menzemer S, Harnew N, Harnew ST, Hasse C, Hatch M, He J, Hecker M, Heinicke K, Heister A, Hennessy K, Henrard P, Henry L, van Herwijnen E, Heß M, Hicheur A, Hill D, Hombach C, Hopchev PH, Hu W, Huard ZC, Hulsbergen W, Humair T, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilten P, Jacobsson R, Jalocha J, Jans E, Jawahery A, Jiang F, John M, Johnson D, Jones CR, Joram C, Jost B, Jurik N, Kandybei S, Karacson M, Kariuki JM, Karodia S, Kazeev N, Kecke M, Keizer F, Kelsey M, Kenzie M, Ketel T, Khairullin E, Khanji B, Khurewathanakul C, Kirn T, Klaver S, Klimaszewski K, Klimkovich T, Koliiev S, Kolpin M, Kopecna R, Koppenburg P, Kosmyntseva A, Kotriakhova S, Kozeiha M, Kravchuk L, Kreps M, Kress F, Krokovny P, Kruse F, Krzemien W, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kuonen AK, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lanfranchi G, Langenbruch C, Latham T, Lazzeroni C, Le Gac R, Leflat A, Lefrançois J, Lefèvre R, Lemaitre F, Lemos Cid E, Leroy O, Lesiak T, Leverington B, Li PR, Li T, Li Y, Li Z, Likhomanenko T, Lindner R, Lionetto F, Lisovskyi V, Liu X, Loh D, Loi A, Longstaff I, Lopes JH, Lucchesi D, Lucio Martinez M, Luo H, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Maev O, Maguire K, Maisuzenko D, Majewski MW, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Marangotto D, Maratas J, Marchand JF, Marconi U, Marin Benito C, Marinangeli M, Marino P, Marks J, Martellotti G, Martin M, Martinelli M, Martinez Santos D, Martinez Vidal F, Massacrier LM, Massafferri A, Matev R, Mathad A, Mathe Z, Matteuzzi C, Mauri A, Maurice E, Maurin B, Mazurov A, McCann M, McNab A, McNulty R, Mead JV, Meadows B, Meaux C, Meier F, Meinert N, Melnychuk D, Merk M, Merli A, Michielin E, Milanes DA, Millard E, Minard MN, Minzoni L, Mitzel DS, Mogini A, Molina Rodriguez J, Mombacher T, Monroy IA, Monteil S, Morandin M, Morello MJ, Morgunova O, Moron J, Morris AB, Mountain R, Muheim F, Mulder M, Müller D, Müller J, Müller K, Müller V, Naik P, Nakada T, Nandakumar R, Nandi A, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neuner M, Nguyen TD, Nguyen-Mau C, Nieswand S, Niet R, Nikitin N, Nikodem T, Nogay A, O'Hanlon DP, Oblakowska-Mucha A, Obraztsov V, Ogilvy S, Oldeman R, Onderwater CJG, Ossowska A, Otalora Goicochea JM, Owen P, Oyanguren A, Pais PR, Palano A, Palutan M, Papanestis A, Pappagallo M, Pappalardo LL, Parker W, Parkes C, Passaleva G, Pastore A, Patel M, Patrignani C, Pearce A, Pellegrino A, Penso G, Pepe Altarelli M, Perazzini S, Perret P, Pescatore L, Petridis K, Petrolini A, Petrov A, Petruzzo M, Picatoste Olloqui E, Pietrzyk B, Pikies M, Pinci D, Pistone A, Piucci A, Placinta V, Playfer S, Plo Casasus M, Polci F, Poli Lener M, Poluektov A, Polyakov I, Polycarpo E, Pomery GJ, Ponce S, Popov A, Popov D, Poslavskii S, Potterat C, Price E, Prisciandaro J, Prouve C, Pugatch V, Puig Navarro A, Pullen H, Punzi G, Qian W, Quagliani R, Quintana B, Rachwal B, Rademacker JH, Rama M, Ramos Pernas M, Rangel MS, Raniuk I, Ratnikov F, Raven G, Ravonel Salzgeber M, Reboud M, Redi F, Reichert S, Dos Reis AC, Remon Alepuz C, Renaudin V, Ricciardi S, Richards S, Rihl M, Rinnert K, Rives Molina V, Robbe P, Robert A, Rodrigues AB, Rodrigues E, Rodriguez Lopez JA, Rogozhnikov A, Roiser S, Rollings A, Romanovskiy V, Romero Vidal A, Ronayne JW, Rotondo M, Rudolph MS, Ruf T, Ruiz Valls P, Ruiz Vidal J, Saborido Silva JJ, Sadykhov E, Sagidova N, Saitta B, Salustino Guimaraes V, Sanchez Mayordomo C, Sanmartin Sedes B, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Sarpis G, Sarti A, Satriano C, Satta A, Saunders DM, Savrina D, Schael S, Schellenberg M, Schiller M, Schindler H, Schmelling M, Schmelzer T, Schmidt B, Schneider O, Schopper A, Schreiner HF, Schubiger M, Schune MH, Schwemmer R, Sciascia B, Sciubba A, Semennikov A, Sepulveda ES, Sergi A, Serra N, Serrano J, Sestini L, Seyfert P, Shapkin M, Shapoval I, Shcheglov Y, Shears T, Shekhtman L, Shevchenko V, Siddi BG, Silva Coutinho R, Silva de Oliveira L, Simi G, Simone S, Sirendi M, Skidmore N, Skwarnicki T, Smith E, Smith IT, Smith J, Smith M, Soares Lavra L, Sokoloff MD, Soler FJP, Souza De Paula B, Spaan B, Spradlin P, Sridharan S, Stagni F, Stahl M, Stahl S, Stefko P, Stefkova S, Steinkamp O, Stemmle S, Stenyakin O, Stepanova M, Stevens H, Stone S, Storaci B, Stracka S, Stramaglia ME, Straticiuc M, Straumann U, Sun J, Sun L, Sutcliffe W, Swientek K, Syropoulos V, Szumlak T, Szymanski M, T'Jampens S, Tayduganov A, Tekampe T, Tellarini G, Teubert F, Thomas E, van Tilburg J, Tilley MJ, Tisserand V, Tobin M, Tolk S, Tomassetti L, Tonelli D, Toriello F, Tourinho Jadallah Aoude R, Tournefier E, Traill M, Tran MT, Tresch M, Trisovic A, Tsaregorodtsev A, Tsopelas P, Tully A, Tuning N, Ukleja A, Usachov A, Ustyuzhanin A, Uwer U, Vacca C, Vagner A, Vagnoni V, Valassi A, Valat S, Valenti G, Vazquez Gomez R, Vazquez Regueiro P, Vecchi S, van Veghel M, Velthuis JJ, Veltri M, Veneziano G, Venkateswaran A, Verlage TA, Vernet M, Vesterinen M, Viana Barbosa JV, Viaud B, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vitti M, Volkov V, Vollhardt A, Voneki B, Vorobyev A, Vorobyev V, Voß C, de Vries JA, Vázquez Sierra C, Waldi R, Wallace C, Wallace R, Walsh J, Wang J, Ward DR, Wark HM, Watson NK, Websdale D, Weiden A, Weisser C, Whitehead M, Wicht J, Wilkinson G, Wilkinson M, Williams M, Williams MP, Williams M, Williams T, Wilson FF, Wimberley J, Winn M, Wishahi J, Wislicki W, Witek M, Wormser G, Wotton SA, Wraight K, Wyllie K, Xie Y, Xu M, Xu Z, Yang Z, Yang Z, Yao Y, Yin H, Yu J, Yuan X, Yushchenko O, Zarebski KA, Zavertyaev M, Zhang L, Zhang Y, Zhelezov A, Zheng Y, Zhu X, Zhukov V, Zonneveld JB, Zucchelli S. Amplitude Analysis of the Decay B[over ¯]^{0}→K_{S}^{0}π^{+}π^{-} and First Observation of the CP Asymmetry in B[over ¯]^{0}→K^{*}(892)^{-}π^{+}. Phys Rev Lett 2018; 120:261801. [PMID: 30004725 DOI: 10.1103/physrevlett.120.261801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2018] [Revised: 03/15/2018] [Indexed: 06/08/2023]
Abstract
The time-integrated untagged Dalitz plot of the three-body hadronic charmless decay B[over ¯]^{0}→K_{S}^{0}π^{+}π^{-} is studied using a pp collision data sample recorded with the LHCb detector, corresponding to an integrated luminosity of 3.0 fb^{-1}. The decay amplitude is described with an isobar model. Relative contributions of the isobar amplitudes to the B[over ¯]^{0}→K_{S}^{0}π^{+}π^{-} decay branching fraction and CP asymmetries of the flavor-specific amplitudes are measured. The CP asymmetry between the conjugate B[over ¯]^{0}→K^{*}(892)^{-}π^{+} and B^{0}→K^{*}(892)^{+}π^{-} decay rates is determined to be -0.308±0.062.
Collapse
Affiliation(s)
- R Aaij
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - B Adeva
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - M Adinolfi
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - Z Ajaltouni
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - S Akar
- University of Cincinnati, Cincinnati, Ohio, USA
| | - J Albrecht
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - F Alessio
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Alexander
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | | | - S Ali
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - G Alkhazov
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | | | - A A Alves
- University of Cincinnati, Cincinnati, Ohio, USA
| | - S Amato
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - S Amerio
- Sezione INFN di Padova, Padova, Italy
| | - Y Amhis
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - L An
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | | | - G Andreassi
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | | | - J E Andrews
- University of Maryland, College Park, Maryland, USA
| | - R B Appleby
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - F Archilli
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - P d'Argent
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - J Arnau Romeu
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - A Artamonov
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - M Artuso
- Syracuse University, Syracuse, New York, USA
| | - E Aslanides
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - M Atzeni
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - G Auriemma
- Sezione INFN di Roma La Sapienza, Roma, Italy
| | - M Baalouch
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - I Babuschkin
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - S Bachmann
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - J J Back
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - A Badalov
- ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - C Baesso
- Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil, associated to Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - S Baker
- Imperial College London, London, United Kingdom
| | - V Balagura
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - W Baldini
- Universita e INFN, Ferrara, Ferrara, Italy
| | - A Baranov
- Yandex School of Data Analysis, Moscow, Russia
| | - R J Barlow
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - C Barschel
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Barsuk
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - W Barter
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - F Baryshnikov
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - V Batozskaya
- National Center for Nuclear Research (NCBJ), Warsaw, Poland
| | - V Battista
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - A Bay
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - L Beaucourt
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - J Beddow
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | | | - I Bediaga
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | - A Beiter
- Syracuse University, Syracuse, New York, USA
| | - L J Bel
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - N Beliy
- University of Chinese Academy of Sciences, Beijing, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - V Bellee
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - N Belloli
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | - K Belous
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - I Belyaev
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - E Ben-Haim
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - G Bencivenni
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - S Benson
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - S Beranek
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - A Berezhnoy
- Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
| | - R Bernet
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - D Berninghoff
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - E Bertholet
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - C Betancourt
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - F Betti
- Sezione INFN di Bologna, Bologna, Italy
| | - M-O Bettler
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M van Beuzekom
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - Ia Bezshyiko
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - S Bifani
- University of Birmingham, Birmingham, United Kingdom
| | - P Billoir
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - A Birnkraut
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - A Bizzeti
- Sezione INFN di Firenze, Firenze, Italy
| | - M Bjørn
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - T Blake
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - F Blanc
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - S Blusk
- Syracuse University, Syracuse, New York, USA
| | - V Bocci
- Sezione INFN di Roma La Sapienza, Roma, Italy
| | - T Boettcher
- Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - A Bondar
- Budker Institute of Nuclear Physics (SB RAS), Novosibirsk, Russia
| | - N Bondar
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - I Bordyuzhin
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - S Borghi
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - M Borisyak
- Yandex School of Data Analysis, Moscow, Russia
| | - M Borsato
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - F Bossu
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - M Boubdir
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - T J V Bowcock
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - E Bowen
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - C Bozzi
- Universita e INFN, Ferrara, Ferrara, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Braun
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - T Britton
- Syracuse University, Syracuse, New York, USA
| | - J Brodzicka
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | - D Brundu
- Sezione INFN di Cagliari, Cagliari, Italy
| | - E Buchanan
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - C Burr
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - A Bursche
- Sezione INFN di Cagliari, Cagliari, Italy
| | - J Buytaert
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - W Byczynski
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Cadeddu
- Sezione INFN di Cagliari, Cagliari, Italy
| | - H Cai
- School of Physics and Technology, Wuhan University, Wuhan, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | | | - R Calladine
- University of Birmingham, Birmingham, United Kingdom
| | - M Calvi
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | | | - A Camboni
- ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - P Campana
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - D H Campora Perez
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - L Capriotti
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - A Carbone
- Sezione INFN di Bologna, Bologna, Italy
| | - G Carboni
- Sezione INFN di Roma Tor Vergata, Roma, Italy
| | | | - A Cardini
- Sezione INFN di Cagliari, Cagliari, Italy
| | - P Carniti
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | - L Carson
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - K Carvalho Akiba
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - G Casse
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - L Cassina
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | - M Cattaneo
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - G Cavallero
- Sezione INFN di Genova, Genova, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Cenci
- Sezione INFN di Pisa, Pisa, Italy
| | - D Chamont
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - M Charles
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - Ph Charpentier
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - M Chefdeville
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - S Chen
- Sezione INFN di Cagliari, Cagliari, Italy
| | - S F Cheung
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - S-G Chitic
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - V Chobanova
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Chrzaszcz
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - A Chubykin
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - P Ciambrone
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - X Cid Vidal
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - G Ciezarek
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - P E L Clarke
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - M Clemencic
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - H V Cliff
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - J Closier
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Cogan
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - E Cogneras
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - V Cogoni
- Sezione INFN di Cagliari, Cagliari, Italy
| | - L Cojocariu
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
| | - P Collins
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - T Colombo
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Comerma-Montells
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Contu
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Cook
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - G Coombs
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Coquereau
- ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - G Corti
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Corvo
- Universita e INFN, Ferrara, Ferrara, Italy
| | - C M Costa Sobral
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - B Couturier
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - G A Cowan
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - D C Craik
- Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - A Crocombe
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - M Cruz Torres
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | - R Currie
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - C D'Ambrosio
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - E Dall'Occo
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - J Dalseno
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - A Davis
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | | | - S De Capua
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - M De Cian
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - J M De Miranda
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | - L De Paula
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | | | - P De Simone
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - C T Dean
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - D Decamp
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - L Del Buono
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - H-P Dembinski
- Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
| | - M Demmer
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - A Dendek
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - D Derkach
- Yandex School of Data Analysis, Moscow, Russia
| | - O Deschamps
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - F Dettori
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - B Dey
- Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - A Di Canto
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Di Nezza
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - H Dijkstra
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - F Dordei
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Dorigo
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Dosil Suárez
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - L Douglas
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - A Dovbnya
- NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
| | - K Dreimanis
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - L Dufour
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - G Dujany
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - P Durante
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Dzhelyadin
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - M Dziewiecki
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Dziurda
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Dzyuba
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - S Easo
- STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
| | - M Ebert
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - U Egede
- Imperial College London, London, United Kingdom
| | - V Egorychev
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - S Eidelman
- Budker Institute of Nuclear Physics (SB RAS), Novosibirsk, Russia
| | - S Eisenhardt
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - U Eitschberger
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - R Ekelhof
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - L Eklund
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - S Ely
- Syracuse University, Syracuse, New York, USA
| | - S Esen
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - H M Evans
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - T Evans
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | | | - N Farley
- University of Birmingham, Birmingham, United Kingdom
| | - S Farry
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - D Fazzini
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | - L Federici
- Sezione INFN di Roma Tor Vergata, Roma, Italy
| | - D Ferguson
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - G Fernandez
- ICCUB, Universitat de Barcelona, Barcelona, Spain
| | | | | | - F Ferrari
- Sezione INFN di Bologna, Bologna, Italy
| | | | - M Ferro-Luzzi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Filippov
- Institute for Nuclear Research of the Russian Academy of Sciences (INR RAN), Moscow, Russia
| | - R A Fini
- Sezione INFN di Bari, Bari, Italy
| | - M Fiorini
- Universita e INFN, Ferrara, Ferrara, Italy
| | - M Firlej
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - C Fitzpatrick
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - T Fiutowski
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - F Fleuret
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - K Fohl
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Fontana
- Sezione INFN di Cagliari, Cagliari, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - D C Forshaw
- Syracuse University, Syracuse, New York, USA
| | - R Forty
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - V Franco Lima
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - M Frank
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Frei
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Fu
- Sezione di Milano, Milano, Italy
| | - W Funk
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - E Furfaro
- Sezione INFN di Roma Tor Vergata, Roma, Italy
| | - C Färber
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - E Gabriel
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - A Gallas Torreira
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - D Galli
- Sezione INFN di Bologna, Bologna, Italy
| | | | - S Gambetta
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - M Gandelman
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | | | - Y Gao
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - L M Garcia Martin
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - J García Pardiñas
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - J Garra Tico
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - L Garrido
- ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - P J Garsed
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - D Gascon
- ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - C Gaspar
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - L Gavardi
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - G Gazzoni
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - D Gerick
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - E Gersabeck
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - M Gersabeck
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - T Gershon
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - Ph Ghez
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - S Gianì
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - V Gibson
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - O G Girard
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - L Giubega
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
| | - K Gizdov
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - V V Gligorov
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - D Golubkov
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - A Golutvin
- Imperial College London, London, United Kingdom
| | - A Gomes
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | - I V Gorelov
- Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
| | - C Gotti
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | - E Govorkova
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - J P Grabowski
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | | | | | - E Graugés
- ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - E Graverini
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | | | - A Grecu
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
| | - R Greim
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - P Griffith
- Sezione INFN di Cagliari, Cagliari, Italy
| | - L Grillo
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | - L Gruber
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - O Grünberg
- Institut für Physik, Universität Rostock, Rostock, Germany, associated to Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - E Gushchin
- Institute for Nuclear Research of the Russian Academy of Sciences (INR RAN), Moscow, Russia
| | - Yu Guz
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - T Gys
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Göbel
- Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil, associated to Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - T Hadavizadeh
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - C Hadjivasiliou
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - G Haefeli
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - C Haen
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S C Haines
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - B Hamilton
- University of Maryland, College Park, Maryland, USA
| | - X Han
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - T H Hancock
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - S Hansmann-Menzemer
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - N Harnew
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - S T Harnew
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - C Hasse
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Hatch
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J He
- University of Chinese Academy of Sciences, Beijing, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - M Hecker
- Imperial College London, London, United Kingdom
| | - K Heinicke
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - A Heister
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - K Hennessy
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - P Henrard
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - L Henry
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - E van Herwijnen
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Heß
- Institut für Physik, Universität Rostock, Rostock, Germany, associated to Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Hicheur
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - D Hill
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - C Hombach
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - P H Hopchev
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - W Hu
- Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - Z C Huard
- University of Cincinnati, Cincinnati, Ohio, USA
| | - W Hulsbergen
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - T Humair
- Imperial College London, London, United Kingdom
| | - M Hushchyn
- Yandex School of Data Analysis, Moscow, Russia
| | - D Hutchcroft
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - P Ibis
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - M Idzik
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - P Ilten
- Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - R Jacobsson
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Jalocha
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - E Jans
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - A Jawahery
- University of Maryland, College Park, Maryland, USA
| | - F Jiang
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - M John
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - D Johnson
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C R Jones
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - C Joram
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - B Jost
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - N Jurik
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - S Kandybei
- NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
| | - M Karacson
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J M Kariuki
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - S Karodia
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - N Kazeev
- Yandex School of Data Analysis, Moscow, Russia
| | - M Kecke
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - F Keizer
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - M Kelsey
- Syracuse University, Syracuse, New York, USA
| | - M Kenzie
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - T Ketel
- Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands
| | | | - B Khanji
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - C Khurewathanakul
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - T Kirn
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - S Klaver
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - K Klimaszewski
- National Center for Nuclear Research (NCBJ), Warsaw, Poland
| | - T Klimkovich
- Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
| | - S Koliiev
- Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
| | - M Kolpin
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - R Kopecna
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - P Koppenburg
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - A Kosmyntseva
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - S Kotriakhova
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - M Kozeiha
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - L Kravchuk
- Institute for Nuclear Research of the Russian Academy of Sciences (INR RAN), Moscow, Russia
| | - M Kreps
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - F Kress
- Imperial College London, London, United Kingdom
| | - P Krokovny
- Budker Institute of Nuclear Physics (SB RAS), Novosibirsk, Russia
| | - F Kruse
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - W Krzemien
- National Center for Nuclear Research (NCBJ), Warsaw, Poland
| | - W Kucewicz
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | - M Kucharczyk
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | - V Kudryavtsev
- Budker Institute of Nuclear Physics (SB RAS), Novosibirsk, Russia
| | - A K Kuonen
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - T Kvaratskheliya
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D Lacarrere
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - G Lafferty
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - A Lai
- Sezione INFN di Cagliari, Cagliari, Italy
| | - G Lanfranchi
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - C Langenbruch
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - T Latham
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - C Lazzeroni
- University of Birmingham, Birmingham, United Kingdom
| | - R Le Gac
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - A Leflat
- Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Lefrançois
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - R Lefèvre
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - F Lemaitre
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - E Lemos Cid
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - O Leroy
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - T Lesiak
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | - B Leverington
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - P-R Li
- University of Chinese Academy of Sciences, Beijing, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - T Li
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - Y Li
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - Z Li
- Syracuse University, Syracuse, New York, USA
| | - T Likhomanenko
- National Research Centre Kurchatov Institute, Moscow, Russia, associated to Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - R Lindner
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - F Lionetto
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - V Lisovskyi
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - X Liu
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - D Loh
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - A Loi
- Sezione INFN di Cagliari, Cagliari, Italy
| | - I Longstaff
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - J H Lopes
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | | | - M Lucio Martinez
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - H Luo
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - A Lupato
- Sezione INFN di Padova, Padova, Italy
| | - E Luppi
- Universita e INFN, Ferrara, Ferrara, Italy
| | - O Lupton
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - X Lyu
- University of Chinese Academy of Sciences, Beijing, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - F Machefert
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - F Maciuc
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
| | - V Macko
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - P Mackowiak
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - S Maddrell-Mander
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - O Maev
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - K Maguire
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - D Maisuzenko
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - M W Majewski
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - S Malde
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - B Malecki
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | - A Malinin
- National Research Centre Kurchatov Institute, Moscow, Russia, associated to Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - T Maltsev
- Budker Institute of Nuclear Physics (SB RAS), Novosibirsk, Russia
| | - G Manca
- Sezione INFN di Cagliari, Cagliari, Italy
| | - G Mancinelli
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | | | - J Maratas
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - J F Marchand
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - U Marconi
- Sezione INFN di Bologna, Bologna, Italy
| | | | - M Marinangeli
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - P Marino
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - J Marks
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | | | - M Martin
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - M Martinelli
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - D Martinez Santos
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - F Martinez Vidal
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | | | - A Massafferri
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | - R Matev
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Mathad
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - Z Mathe
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Matteuzzi
- Universita & INFN, Milano-Bicocca, Milano, Italy
| | - A Mauri
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - E Maurice
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - B Maurin
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - A Mazurov
- University of Birmingham, Birmingham, United Kingdom
| | - M McCann
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Imperial College London, London, United Kingdom
| | - A McNab
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - R McNulty
- School of Physics, University College Dublin, Dublin, Ireland
| | - J V Mead
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - B Meadows
- University of Cincinnati, Cincinnati, Ohio, USA
| | - C Meaux
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - F Meier
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - N Meinert
- Institut für Physik, Universität Rostock, Rostock, Germany, associated to Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - D Melnychuk
- National Center for Nuclear Research (NCBJ), Warsaw, Poland
| | - M Merk
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - A Merli
- Sezione di Milano, Milano, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - D A Milanes
- Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia, associated to LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - E Millard
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - M-N Minard
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - L Minzoni
- Universita e INFN, Ferrara, Ferrara, Italy
| | - D S Mitzel
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Mogini
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - T Mombacher
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - I A Monroy
- Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia, associated to LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - S Monteil
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | | | | | - O Morgunova
- National Research Centre Kurchatov Institute, Moscow, Russia, associated to Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - J Moron
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - A B Morris
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - R Mountain
- Syracuse University, Syracuse, New York, USA
| | - F Muheim
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - M Mulder
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - D Müller
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - J Müller
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - K Müller
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - V Müller
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - P Naik
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - T Nakada
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - R Nandakumar
- STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
| | - A Nandi
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - I Nasteva
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - M Needham
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - N Neri
- Sezione di Milano, Milano, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Neubert
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - N Neufeld
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Neuner
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - T D Nguyen
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - C Nguyen-Mau
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - S Nieswand
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - R Niet
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - N Nikitin
- Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
| | - T Nikodem
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Nogay
- National Research Centre Kurchatov Institute, Moscow, Russia, associated to Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - D P O'Hanlon
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - A Oblakowska-Mucha
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - V Obraztsov
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - S Ogilvy
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - R Oldeman
- Sezione INFN di Cagliari, Cagliari, Italy
| | - C J G Onderwater
- Van Swinderen Institute, University of Groningen, Groningen, The Netherlands, associated to Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - A Ossowska
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | | | - P Owen
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - A Oyanguren
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - P R Pais
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - A Palano
- Sezione INFN di Bari, Bari, Italy
| | - M Palutan
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Papanestis
- STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
| | | | | | - W Parker
- University of Maryland, College Park, Maryland, USA
| | - C Parkes
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - G Passaleva
- Sezione INFN di Firenze, Firenze, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - M Patel
- Imperial College London, London, United Kingdom
| | | | - A Pearce
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Pellegrino
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - G Penso
- Sezione INFN di Roma La Sapienza, Roma, Italy
| | - M Pepe Altarelli
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Perazzini
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Perret
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - L Pescatore
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - K Petridis
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | | | - A Petrov
- National Research Centre Kurchatov Institute, Moscow, Russia, associated to Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | | | | | - B Pietrzyk
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - M Pikies
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | - D Pinci
- Sezione INFN di Roma La Sapienza, Roma, Italy
| | - A Pistone
- Sezione INFN di Genova, Genova, Italy
| | - A Piucci
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - V Placinta
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
| | - S Playfer
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - M Plo Casasus
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - F Polci
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - M Poli Lener
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - A Poluektov
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - I Polyakov
- Syracuse University, Syracuse, New York, USA
| | - E Polycarpo
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - G J Pomery
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - S Ponce
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Popov
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - D Popov
- Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Poslavskii
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - C Potterat
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - E Price
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - J Prisciandaro
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - C Prouve
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - V Pugatch
- Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
| | - A Puig Navarro
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - H Pullen
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - G Punzi
- Sezione INFN di Pisa, Pisa, Italy
| | - W Qian
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - R Quagliani
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - B Quintana
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - B Rachwal
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - J H Rademacker
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - M Rama
- Sezione INFN di Pisa, Pisa, Italy
| | - M Ramos Pernas
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - M S Rangel
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - I Raniuk
- NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
| | - F Ratnikov
- Yandex School of Data Analysis, Moscow, Russia
| | - G Raven
- Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands
| | | | - M Reboud
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - F Redi
- Imperial College London, London, United Kingdom
| | - S Reichert
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - A C Dos Reis
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | - C Remon Alepuz
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - V Renaudin
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - S Ricciardi
- STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
| | - S Richards
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - M Rihl
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - K Rinnert
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | | | - P Robbe
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - A Robert
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - A B Rodrigues
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | - E Rodrigues
- University of Cincinnati, Cincinnati, Ohio, USA
| | - J A Rodriguez Lopez
- Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia, associated to LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - S Roiser
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Rollings
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - V Romanovskiy
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - A Romero Vidal
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - J W Ronayne
- School of Physics, University College Dublin, Dublin, Ireland
| | - M Rotondo
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - M S Rudolph
- Syracuse University, Syracuse, New York, USA
| | - T Ruf
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Ruiz Valls
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - J Ruiz Vidal
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | | | - E Sadykhov
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - N Sagidova
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - B Saitta
- Sezione INFN di Cagliari, Cagliari, Italy
| | | | - C Sanchez Mayordomo
- Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia-CSIC, Valencia, Spain, associated to ICCUB, Universitat de Barcelona, Barcelona, Spain
| | - B Sanmartin Sedes
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | - M Santimaria
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | | | - G Sarpis
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - A Sarti
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - C Satriano
- Sezione INFN di Roma La Sapienza, Roma, Italy
| | - A Satta
- Sezione INFN di Roma Tor Vergata, Roma, Italy
| | - D M Saunders
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - D Savrina
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
- Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
| | - S Schael
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - M Schellenberg
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - M Schiller
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - H Schindler
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Schmelling
- Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
| | - T Schmelzer
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - B Schmidt
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - O Schneider
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - A Schopper
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - M Schubiger
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - M-H Schune
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - R Schwemmer
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - B Sciascia
- Laboratori Nazionali dell'INFN di Frascati, Frascati, Italy
| | - A Sciubba
- Sezione INFN di Roma La Sapienza, Roma, Italy
| | - A Semennikov
- Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - E S Sepulveda
- LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - A Sergi
- University of Birmingham, Birmingham, United Kingdom
| | - N Serra
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - J Serrano
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - L Sestini
- Sezione INFN di Padova, Padova, Italy
| | - P Seyfert
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Shapkin
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - I Shapoval
- NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
| | - Y Shcheglov
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - T Shears
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - L Shekhtman
- Budker Institute of Nuclear Physics (SB RAS), Novosibirsk, Russia
| | - V Shevchenko
- National Research Centre Kurchatov Institute, Moscow, Russia, associated to Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - B G Siddi
- Universita e INFN, Ferrara, Ferrara, Italy
| | | | | | - G Simi
- Sezione INFN di Padova, Padova, Italy
| | - S Simone
- Sezione INFN di Bari, Bari, Italy
| | - M Sirendi
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - N Skidmore
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | | | - E Smith
- Imperial College London, London, United Kingdom
| | - I T Smith
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - J Smith
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - M Smith
- Imperial College London, London, United Kingdom
| | - L Soares Lavra
- Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
| | | | - F J P Soler
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - B Souza De Paula
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - B Spaan
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - P Spradlin
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - S Sridharan
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - F Stagni
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Stahl
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - S Stahl
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Stefko
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - S Stefkova
- Imperial College London, London, United Kingdom
| | - O Steinkamp
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - S Stemmle
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - O Stenyakin
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - M Stepanova
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - H Stevens
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - S Stone
- Syracuse University, Syracuse, New York, USA
| | - B Storaci
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | | | - M E Stramaglia
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - M Straticiuc
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
| | - U Straumann
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - J Sun
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - L Sun
- School of Physics and Technology, Wuhan University, Wuhan, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - W Sutcliffe
- Imperial College London, London, United Kingdom
| | - K Swientek
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - V Syropoulos
- Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands
| | - T Szumlak
- AGH-University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
| | - M Szymanski
- University of Chinese Academy of Sciences, Beijing, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - S T'Jampens
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - A Tayduganov
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - T Tekampe
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | | | - F Teubert
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - E Thomas
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J van Tilburg
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - M J Tilley
- Imperial College London, London, United Kingdom
| | - V Tisserand
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - M Tobin
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - S Tolk
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | | | | | - F Toriello
- Syracuse University, Syracuse, New York, USA
| | | | - E Tournefier
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - M Traill
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - M T Tran
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - M Tresch
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - A Trisovic
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - P Tsopelas
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - A Tully
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - N Tuning
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - A Ukleja
- National Center for Nuclear Research (NCBJ), Warsaw, Poland
| | - A Usachov
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | | | - U Uwer
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - C Vacca
- Sezione INFN di Cagliari, Cagliari, Italy
| | - A Vagner
- National Research Tomsk Polytechnic University, Tomsk, Russia, associated to Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
| | - V Vagnoni
- Sezione INFN di Bologna, Bologna, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Valassi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Valat
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - G Valenti
- Sezione INFN di Bologna, Bologna, Italy
| | - R Vazquez Gomez
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - S Vecchi
- Universita e INFN, Ferrara, Ferrara, Italy
| | - M van Veghel
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - J J Velthuis
- H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
| | - M Veltri
- Sezione INFN di Firenze, Firenze, Italy
| | - G Veneziano
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | | | - T A Verlage
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - M Vernet
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - M Vesterinen
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - J V Viana Barbosa
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - B Viaud
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - D Vieira
- University of Chinese Academy of Sciences, Beijing, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - M Vieites Diaz
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - H Viemann
- Institut für Physik, Universität Rostock, Rostock, Germany, associated to Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | | | - M Vitti
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - V Volkov
- Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
| | - A Vollhardt
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - B Voneki
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Vorobyev
- Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
| | - V Vorobyev
- Budker Institute of Nuclear Physics (SB RAS), Novosibirsk, Russia
| | - C Voß
- I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - J A de Vries
- Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
| | - C Vázquez Sierra
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - R Waldi
- Institut für Physik, Universität Rostock, Rostock, Germany, associated to Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - C Wallace
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - R Wallace
- School of Physics, University College Dublin, Dublin, Ireland
| | - J Walsh
- Sezione INFN di Pisa, Pisa, Italy
| | - J Wang
- Syracuse University, Syracuse, New York, USA
| | - D R Ward
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - H M Wark
- Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
| | - N K Watson
- University of Birmingham, Birmingham, United Kingdom
| | - D Websdale
- Imperial College London, London, United Kingdom
| | - A Weiden
- Physik-Institut, Universität Zürich, Zürich, Switzerland
| | - C Weisser
- Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - M Whitehead
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Wicht
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - G Wilkinson
- Department of Physics, University of Oxford, Oxford, United Kingdom
| | - M Wilkinson
- Syracuse University, Syracuse, New York, USA
| | - M Williams
- School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
| | - M P Williams
- University of Birmingham, Birmingham, United Kingdom
| | - M Williams
- Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - T Williams
- University of Birmingham, Birmingham, United Kingdom
| | - F F Wilson
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
| | - J Wimberley
- University of Maryland, College Park, Maryland, USA
| | - M Winn
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - J Wishahi
- Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
| | - W Wislicki
- National Center for Nuclear Research (NCBJ), Warsaw, Poland
| | - M Witek
- Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
| | - G Wormser
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - S A Wotton
- Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
| | - K Wraight
- School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
| | - K Wyllie
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y Xie
- Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - M Xu
- Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - Z Xu
- LAPP, Université Savoie Mont-Blanc, CNRS/IN2P3, Annecy-Le-Vieux, France
| | - Z Yang
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - Z Yang
- University of Maryland, College Park, Maryland, USA
| | - Y Yao
- Syracuse University, Syracuse, New York, USA
| | - H Yin
- Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - J Yu
- Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - X Yuan
- Syracuse University, Syracuse, New York, USA
| | - O Yushchenko
- Institute for High Energy Physics (IHEP), Protvino, Russia
| | - K A Zarebski
- University of Birmingham, Birmingham, United Kingdom
| | - M Zavertyaev
- Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
| | - L Zhang
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - Y Zhang
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - A Zhelezov
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - Y Zheng
- University of Chinese Academy of Sciences, Beijing, China, associated to Center for High Energy Physics, Tsinghua University, Beijing, China
| | - X Zhu
- Center for High Energy Physics, Tsinghua University, Beijing, China
| | - V Zhukov
- Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
| | - J B Zonneveld
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | | |
Collapse
|